351
|
High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom. Bone Marrow Transplant 2017; 52:1268-1272. [DOI: 10.1038/bmt.2017.101] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2017] [Revised: 03/29/2017] [Accepted: 04/25/2017] [Indexed: 12/21/2022]
|
352
|
Ambady P, Fu R, Netto JP, Kersch C, Firkins J, Doolittle ND, Neuwelt EA. Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease. Fluids Barriers CNS 2017; 14:16. [PMID: 28577579 PMCID: PMC5457655 DOI: 10.1186/s12987-017-0064-3] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2017] [Accepted: 05/22/2017] [Indexed: 12/22/2022] Open
Abstract
Background and purpose The radiologic features and patterns of primary central nervous system lymphoma (PCNSL) at initial presentation are well described. High response rates can be achieved with first-line high-dose methotrexate (HD-MTX) based regimens, yet many relapse within 2 years of diagnosis. We describe the pattern of relapse and review the potential mechanisms involved in relapse. Methods We identified 78 consecutive patients who attained complete radiographic response (CR) during or after first-line treatment for newly diagnosed PCNSL (CD20+, diffuse large B cell type). Patients were treated with HD-MTX based regimen in conjunction with blood–brain barrier disruption (HD-MTX/BBBD); 44 subsequently relapsed. Images and medical records of these 44 consecutive patients were retrospectively reviewed. The anatomical location of enhancing lesions at initial diagnosis and at the time of relapse were identified and compared. Results 37/44 patients fulfilled inclusion criteria and had new measureable enhancing lesions at relapse; the pattern and location of relapse of these 37 patients were identified. At relapse, the new enhancement was at a spatially distinct site in 30 of 37 patients. Local relapse was found only in seven patients. Discussion Unlike gliomas, the majority of PCNSL had radiographic relapse at spatially distinct anatomical locations within the brain behind a previously intact neurovascular unit (NVU), and in few cases outside, the central nervous system (CNS). This may suggest either (1) reactivation of occult reservoirs behind an intact NVU in the CNS (or ocular) or (2) seeding from bone marrow or other extra CNS sites. Conclusion Recognizing patterns of relapse is key for early detection and may provide insight into potential mechanisms of relapse as well as help develop strategies to extend duration of complete response.
Collapse
Affiliation(s)
- Prakash Ambady
- Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, L603, Portland, OR, 97239, USA.,Portland Veterans Affairs Medical Center, Portland, OR, USA
| | - Rongwei Fu
- School of Public Health, Oregon Health & Science University, Portland, OR, USA.,Department of Emergency Medicine, Oregon Health & Science University, Portland, OR, USA
| | - Joao Prola Netto
- Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, L603, Portland, OR, 97239, USA.,Department of Radiology, Oregon Health & Science University, Portland, OR, USA
| | - Cymon Kersch
- Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, L603, Portland, OR, 97239, USA
| | - Jenny Firkins
- Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, L603, Portland, OR, 97239, USA
| | - Nancy D Doolittle
- Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, L603, Portland, OR, 97239, USA
| | - Edward A Neuwelt
- Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, L603, Portland, OR, 97239, USA. .,Portland Veterans Affairs Medical Center, Portland, OR, USA. .,Department of Neurosurgery, Oregon Health & Science University, Portland, OR, USA.
| |
Collapse
|
353
|
Kasenda B, Ihorst G, Schroers R, Korfel A, Schmidt-Wolf I, Egerer G, von Baumgarten L, Röth A, Bloehdorn J, Möhle R, Binder M, Keller U, Lamprecht M, Pfreundschuh M, Valk E, Fricker H, Schorb E, Fritsch K, Finke J, Illerhaus G. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. Leukemia 2017; 31:2623-2629. [PMID: 28559537 DOI: 10.1038/leu.2017.170] [Citation(s) in RCA: 59] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2017] [Revised: 05/08/2017] [Accepted: 05/15/2017] [Indexed: 01/08/2023]
Abstract
To investigate safety and efficacy of high-dose chemotherapy followed by autologous stem cell transplantation (HCT-ASCT) in relapsed/refractory (r/r) primary central nervous system lymphoma (PCNSL), we conducted a single-arm multicentre study for immunocompetent patients (<66 years) with PCNSL failing high-dose methotrexate)-based chemotherapy. Induction consisted of two courses of rituximab (375 mg/m2), high-dose cytarabine (2 × 3 g/m2) and thiotepa (40 mg/m2) with collection of stem cells in between. Conditioning for HCT-ASCT consisted of rituximab 375 mg/m2, carmustine 400 mg/m2 and thiotepa (4 × 5 mg/kg). Patients commenced HCT-ASCT irrespective of response after induction. Patients not achieving complete remission (CR) after HCT-ASCT received whole-brain radiotherapy. Primary end point was CR after HCT-ASCT. We enrolled 39 patients; median age and Karnofsky performance score are 57 years and 90%, respectively. About 28 patients had relapsed and 8 refractory disease. About 22 patients responded to induction and 32 patients commenced HCT-ASCT. About 22 patients (56.4%) achieved CR after HCT-ASCT. Respective 2-year progression-free survival (PFS) and overall survival (OS) rates were 46.0% (median PFS 12.4 months) and 56.4%; median OS not reached. We recorded four treatment-related deaths. Thiotepa-based HCT-ASCT is an effective treatment option in eligible patients with r/r PCNSL. Comparative studies are needed to further scrutinise the role of HCT-ASCT in the salvage setting.
Collapse
Affiliation(s)
- B Kasenda
- Department of Haematology/Oncology, Klinikum Stuttgart, Stuttgart, Germany.,Department of Medical Oncology & Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
| | - G Ihorst
- Clinical Trials Unit, Medical Centre - University of Freiburg, Freiburg, Germany
| | - R Schroers
- Department of Medicine, Hematology and Oncology, Ruhr-University of Bochum, Knappschaftskrankenhaus Bochum-Langendreer, Bochum, Germany
| | - A Korfel
- Department of Hematology, Oncology and Tumor Immunology, Charite University Medicine, Berlin, Germany
| | - I Schmidt-Wolf
- Department of Internal Medicine III, Center for Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany
| | - G Egerer
- Department of Haematology and Oncology, Heidelberg University, Heidelberg, Germany
| | - L von Baumgarten
- Department of Neurology, University Hospital Munich LMU, Munich, Germany
| | - A Röth
- Medical Faculty, Department of Haematology, University of Duisburg-Essen, Essen, Germany
| | - J Bloehdorn
- Department of Internal Medicine III, University of Ulm, Ulm, Germany
| | - R Möhle
- Department of Haematology and Oncology, University Tübingen, Tübingen, Germany
| | - M Binder
- Department of Oncology and Hematology, University of Hamburg, Hamburg, Germany
| | - U Keller
- III Medical Department, Technische Universität München, Munich, Germany
| | - M Lamprecht
- Department of Internal Medicine II, University Hospital of Schleswig-Holstein, Campus Kiel, Germany
| | - M Pfreundschuh
- Klinik für Innere Medizin I, Universität des Saarlandes, Homburg, Germany
| | - E Valk
- Department of Haematology/Oncology, Klinikum Stuttgart, Stuttgart, Germany
| | - H Fricker
- Department of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Freiburg, Germany
| | - E Schorb
- Department of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Freiburg, Germany
| | - K Fritsch
- Department of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Freiburg, Germany
| | - J Finke
- Department of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Freiburg, Germany
| | - G Illerhaus
- Department of Haematology/Oncology, Klinikum Stuttgart, Stuttgart, Germany.,Department of Haematology, Oncology and Stem Cell Transplantation, University Hospital Freiburg, Freiburg, Germany
| |
Collapse
|
354
|
Sun Y, Wang Y, Han S, Xing B, Li H, Zhu Y, Zhou S, Wang X, Xu J, Tao R. Efficacy and safety of pemetrexed on recurrent primary central nervous system lymphomas in China: a prospective study. Onco Targets Ther 2017; 10:2595-2600. [PMID: 28553124 PMCID: PMC5440074 DOI: 10.2147/ott.s134684] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND Pemetrexed, a new and novel agent for primary central nervous system lymphomas (PCNSLs), has shown to be efficient as a savage therapy for recurrent PCNSLs. However, more studies are needed. A prospective study was performed on 17 recurrent PCNSL patients with pemetrexed at Shandong Tumor Hospital in China to assess the efficacy and safety of pemetrexed for recurrent PCNSL patients. MATERIALS AND METHODS The medical records and imaging data on all the cases of recurrent PCNSL patients with pemetrexed in our study were collected during August 2012 and April 2015. Folic acid, B12, and dexamethasone were used to induce toxicities related to pemetrexed. Patients were treated with pemetrexed at a dose of 900 mg/m2 intravenously every 3 weeks, and one cycle consists of 6 weeks. RESULTS A total of 17 cases of recurrent PCNSL patients were enrolled in our study, including 10 males and 7 females with a median age of 66.2 years (ranging from 35 to 81). After the treatment, five cases had complete remission, with partial remission in five cases, stable disease in four cases, and progressive disease in three cases. Consequently, the overall response rate was 58.8%, and the disease control rate was 82.4%. The median overall survival was 7.8 months (95% confidence interval: 5.9-9.6 months) in the study of recurrent PCNSL patients. CONCLUSION This study has been the first clinical trial that applied pemetrexed to treat recurrent PCNSL patients in China, and results indicated that chemotherapy using large pemetrexed may become an effective treatment for PCNSL recurrence with modest toxicity.
Collapse
Affiliation(s)
- Yi Sun
- School of Medicine and Life Sciences, University of Jinan, Shandong Academy of Medical Sciences.,Department of Neurosurgery, Shandong Cancer Hospital affiliated to Shandong University.,Department of Neurosurgery, The Sixth People's Hospital of Jinan
| | - Yong Wang
- Department of Neurosurgery, Shandong Cancer Hospital affiliated to Shandong University
| | - Shaolong Han
- Department of Neurosurgery, The Sixth People's Hospital of Jinan
| | - Bo Xing
- Department of Neurosurgery, The Sixth People's Hospital of Jinan
| | - Hong Li
- Department of Ophthalmology and Otolaryngology, The Sixth People's Hospital of Jinan, Jinan City, Shandong Province, People's Republic of China
| | - Yufang Zhu
- Department of Neurosurgery, Shandong Cancer Hospital affiliated to Shandong University
| | - Shizhen Zhou
- Department of Neurosurgery, Shandong Cancer Hospital affiliated to Shandong University
| | - Xiuhua Wang
- Department of Neurosurgery, Shandong Cancer Hospital affiliated to Shandong University
| | - Jun Xu
- Department of Neurosurgery, Shandong Cancer Hospital affiliated to Shandong University
| | - Rongjie Tao
- Department of Neurosurgery, Shandong Cancer Hospital affiliated to Shandong University
| |
Collapse
|
355
|
The prognostic role of CD68 and FoxP3 expression in patients with primary central nervous system lymphoma. Ann Hematol 2017; 96:1163-1173. [PMID: 28508176 DOI: 10.1007/s00277-017-3014-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2016] [Accepted: 05/02/2017] [Indexed: 01/20/2023]
Abstract
The prognostic role of CD68 and FoxP3 in primary central nervous system lymphoma (PCNSL) has not been evaluated. Thus, we examined the prognostic significance of CD68 and FoxP3 expression in tumor samples of 76 newly diagnosed immunocompetent PCNSL patients. All patients were treated initially with high-dose methotrexate (HD-MTX)-based chemotherapy, and 16 (21.1%) patients received upfront autologous stem cell transplantation (ASCT) consolidation. High expression of CD68 (>55 cells/high-power field) or FoxP3 (>15 cells/high-power field) was observed in 10 patients, respectively. High CD68 expression was associated with inferior overall survival (OS) and progression-free survival (PFS) in multivariate analysis (P = 0.023 and P = 0.021, respectively). In addition, we performed subgroup analysis based on upfront ASCT. High CD68 expression was also associated with inferior OS and PFS in multivariate analysis (P = 0.013 and P < 0.001, respectively) among patients who did not receive upfront ASCT (n = 60), but not in patients who received upfront ASCT. The expression of FoxP3 was not significantly associated with survival. Therefore, we identified a prognostic significance of high CD68 expression in PCNSL, which suggests a need for further clinical trials and biological studies on the role of PCNSL tumor microenvironment.
Collapse
|
356
|
Citterio G, Reni M, Gatta G, Ferreri AJM. Primary central nervous system lymphoma. Crit Rev Oncol Hematol 2017; 113:97-110. [DOI: 10.1016/j.critrevonc.2017.03.019] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2016] [Revised: 02/24/2017] [Accepted: 03/15/2017] [Indexed: 12/26/2022] Open
|
357
|
de-Bonilla-Damiá Á, Fernández-López R, Capote-Huelva FJ, de la Cruz-Vicente F, Egea-Guerrero JJ, Borrego-Dorado I. Role of 18F-FDG PET/CT in primary brain lymphoma. Rev Esp Med Nucl Imagen Mol 2017; 36:298-303. [PMID: 28438519 DOI: 10.1016/j.remn.2017.03.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2016] [Revised: 03/02/2017] [Accepted: 03/15/2017] [Indexed: 01/02/2023]
Abstract
OBJECTIVE To study the usefulness of 18F-FDG PET/CT in the initial evaluation and in the response assessment in primary brain lymphoma. MATERIAL AND METHODS A retrospective analysis was carried out on 18 patients diagnosed with primary brain lymphoma, a histological subtype of diffuse large B-cell lymphoma, on whom an initial 18F-FDG PET/CT and MRI was performed, with 7 of the cases being analysed after the completion of treatment in order to assess response and clinical follow up. RESULTS Initial 18F-FDG PET/CT showed 26 hypermetabolic foci, whereas 46 lesions were detected by MRI. The average SUV maximum of the lesions was 17.56 with T/N 3.55. The concordance of both tests for identifying the same number of lesions was moderate, obtaining a kappa index of 0.395 (P<.001). In the evaluation of treatment, MRI identified 16 lesions compared to 7 pathological accumulations observed by 18F-FDG PET/CT. The concordance of both tests to assess type of response to treatment was moderate (kappa index 0.41) (P=.04). In both the initial evaluation and the assessment of the response to treatment, PET/CT led to a change strategy in 22% of patients who had lesions outside the cerebral parenchyma. CONCLUSIONS MRI appears to be the method of choice for detecting brain disease in patients with primary brain lymphoma, whereas 18F-FDG PET/CT seems to play a relevant role in the assessment of extra-cerebral disease.
Collapse
Affiliation(s)
- Á de-Bonilla-Damiá
- Servicio de Medicina Nuclear, Hospital Universitario Virgen del Rocío, Sevilla, España.
| | - R Fernández-López
- Servicio de Medicina Nuclear, Hospital Universitario Virgen del Rocío, Sevilla, España
| | - F J Capote-Huelva
- Unidad de Gestión Clínica de Hematología y Hemoterapia, Hospital Universitario Puerta del Mar, Cádiz, España
| | - F de la Cruz-Vicente
- Unidad de Gestión Clínica de Hematología y Hemoterapia, Hospital Universitario Virgen del Rocío, Sevilla, España
| | - J J Egea-Guerrero
- Unidad de Gestión Clínica de Medicina Intensiva, Hospital Universitario Virgen del Rocío, IBiS, CSIC, Universidad de Sevilla, Sevilla, España
| | - I Borrego-Dorado
- Servicio de Medicina Nuclear, Hospital Universitario Virgen del Rocío, Sevilla, España
| |
Collapse
|
358
|
Houillier C, Ghesquières H, Chabrot C, Soussain C, Ahle G, Choquet S, Nicolas-Virelizier E, Bay JO, Vargaftig J, Gaultier C, Touitou V, Martin-Duverneuil N, Cassoux N, Le Garff-Tavernier M, Costopoulos M, Faurie P, Hoang-Xuan K. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study. J Neurooncol 2017; 133:315-320. [DOI: 10.1007/s11060-017-2435-7] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2016] [Accepted: 04/15/2017] [Indexed: 10/19/2022]
|
359
|
DeFilipp Z, Li S, El-Jawahri A, Armand P, Nayak L, Wang N, Batchelor TT, Chen YB. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. Cancer 2017; 123:3073-3079. [PMID: 28369839 DOI: 10.1002/cncr.30695] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2017] [Revised: 03/07/2017] [Accepted: 03/08/2017] [Indexed: 11/07/2022]
Abstract
BACKGROUND High-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT) is a therapeutic option for patients with primary central nervous system lymphoma (PCNSL). To the authors' knowledge, data are limited regarding its use among patients in first complete remission (CR1) with the CNS-directed conditioning regimen of thiotepa, busulfan, and cyclophosphamide (TBC). METHODS A retrospective analysis of patients with PCNSL in CR1 who underwent transplantation using a TBC-based conditioning regimen at 2 academic institutions was performed. RESULTS Forty-six consecutive patients who underwent HDC-ASCT while in CR1 were identified. The most common induction regimen was high-dose methotrexate plus temozolomide and rituximab (59%). No patients received whole-brain radiotherapy. A total of 40 patients (87%) received cytarabine before undergoing ASCT as either induction intensification, early consolidation therapy, or mobilization. The median time from diagnosis to transplantation was 6 months (range, 4-15 months). The median age of the patients at the time of transplantation was 59 years (range, 27-69 years). With a median follow-up of 2.7 years after ASCT (range, 6 months-7.5 years), the Kaplan-Meier estimates of 2-year overall survival and progression-free survival were 95% (95% confidence interval [95% CI], 80%-99%) and 92% (95% CI, 77%-97%), respectively. The most common toxicities were severe mucositis (35%) and bacterial infections occurring within 100 days of transplantation (35%). The estimated 2-year nonrecurrence mortality rate was 2.9% (95% CI, 0.2%-13.4%). CONCLUSIONS HDC-ASCT with a CNS-directed conditioning regimen such as TBC should be considered for patients with PCNSL who are in CR1 because this approach is associated with encouraging disease control and survival in this select patient population. Cancer 2017;123:3073-79. © 2017 American Cancer Society.
Collapse
Affiliation(s)
- Zachariah DeFilipp
- Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts
| | - Shuli Li
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Areej El-Jawahri
- Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts
| | - Philippe Armand
- Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Lakshmi Nayak
- Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Nancy Wang
- Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, Massachusetts
| | - Tracy T Batchelor
- Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, Massachusetts
| | - Yi-Bin Chen
- Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts
| |
Collapse
|
360
|
Primary central nervous system lymphoma: essential points in diagnosis and management. Med Oncol 2017; 34:61. [PMID: 28315229 DOI: 10.1007/s12032-017-0920-7] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2017] [Accepted: 03/14/2017] [Indexed: 12/19/2022]
Abstract
Primary central nervous system lymphoma (PCNSL) is an extra-nodal non-Hodgkin lymphoma. PCNSL is defined as lymphoma involving the brain, leptomeninges, eyes, or spinal cord without evidence of lymphoma outside the CNS. Treatment includes induction with chemotherapy and consolidation with whole-brain radiotherapy or high-dose chemotherapy supported by autologous stem cell transplantation. High-dose methotrexate is the most important drug in cases with PCNSL, and this drug will be used in combination with small molecules, BTK inhibitors, new monoclonal antibodies, and checkpoint blockers.
Collapse
|
361
|
Schlegel U, Korfel A. The challenge of adequate imaging surveillance in primary central nervous system lymphoma. Neuro Oncol 2017; 19:307-308. [PMID: 28025387 DOI: 10.1093/neuonc/now273] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Affiliation(s)
- Uwe Schlegel
- Department of Neurology, University-Hospital Bochum, Germany
| | - Agnieszka Korfel
- Department of Internal Medicine, Hematology and Oncology, University Hospital Charité Berlin, Germany
| |
Collapse
|
362
|
Korfel A, Schlegel U, Johnson DR, Kaufmann TJ, Giannini C, Hirose T. Case-based review: primary central nervous system lymphoma. Neurooncol Pract 2017; 4:46-59. [PMID: 31386044 DOI: 10.1093/nop/npw033] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2016] [Indexed: 11/14/2022] Open
Abstract
Primary CNS lymphoma (PCNSL) is a rare diffuse large B-cell lymphoma originating within the central nervous system. The overall incidence of PCNSL is rising, particularly in the elderly population. Immunosuppression is a strong risk factor, but most patients with this tumor are apparently immunocompetent. Diagnosis of PCNSL can be challenging. Non-invasive or minimally invasive tests such as ophthalmological evaluation and spinal fluid analysis may be useful, but the majority of patients require tumor biopsy for definitive diagnosis. Our knowledge concerning optimum treatment of PCNSL is fragmentary due to paucity of adequately sized trials. Most patients are now initially treated with high-dose-methotrexate-based chemotherapy alone, as the addition of whole-brain radiotherapy at standard doses has not been shown to increase survival and does increase the risk of neurological toxicity. Ongoing trials are addressing issues such as the roles of reduced-dose radiotherapy, the addition of the CD20 antibody rituximab to chemotherapy, high-dose chemotherapy followed by autologous stem cell transplantation, and maintenance therapy in the primary management of PCNSL.
Collapse
Affiliation(s)
- Agnieszka Korfel
- Department of Hematology, Oncology and Tumor Immunology, Charite University Medicine, Berlin, Germany (A.K.)
| | - Uwe Schlegel
- Department of Neurology, University Hospital Bochum Knappschaftskrankenhaus, Bochum, Germany (U.S.)
| | - Derek R Johnson
- Department of Radiology, Mayo Clinic, Rochester, MN, USA (D.R.J., T.K.)
| | | | - Caterina Giannini
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA (C.G.)
| | - Takanori Hirose
- Department of Pathology, Kobe University Hospital, Kobe City, Japan (T.H.)
| |
Collapse
|
363
|
Nijland M, Jansen A, Doorduijn JK, Enting RH, Bromberg JEC, Kluin-Nelemans HC. Treatment of initial parenchymal central nervous system involvement in systemic aggressive B-cell lymphoma. Leuk Lymphoma 2017; 58:1-6. [DOI: 10.1080/10428194.2017.1285026] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Marcel Nijland
- Department of Haematology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands
| | - Anne Jansen
- Department of Neurology, Canisius-Wilhelmina Hospital, Nijmegen, Netherlands
| | | | - Roelien H. Enting
- Department of Neurology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands
| | | | - Hanneke C. Kluin-Nelemans
- Department of Haematology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands
| |
Collapse
|
364
|
Umino K, Fujiwara SI, Sato K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Yamamoto C, Hatano K, Okazuka K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y. High-Dose Methotrexate and Cytarabine-Based Multi-Agent Chemotherapy (Modified Bonn Protocol) for Systemic Lymphoma with CNS Involvement. Acta Haematol 2017; 137:93-99. [PMID: 28118621 DOI: 10.1159/000454890] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2016] [Accepted: 11/29/2016] [Indexed: 11/19/2022]
Abstract
The prognosis of patients with systemic lymphoma with central nervous system (CNS) involvement is very poor and there is no established standard therapy. We retrospectively analyzed 18 patients (4 untreated and 14 relapsed) with systemic lymphoma with CNS involvement who received methotrexate and cytarabine-based multiagent chemotherapy (modified Bonn protocol). Complete and partial responses were achieved in 56 and 22% of the patients, respectively. The 1-year overall survival (OS) and progression-free survival (PFS) was 81.0 and 39.2%, respectively. Patients with parenchymal involvement showed a better 1-year PFS than those with either leptomeningeal involvement or both. In a multivariate analysis, poor performance status (PS) was the only independent prognostic factor for the 1-year OS and PFS (HR 10.8, 95% CI 1.09-108, p = 0.042; HR 20.8, 95% CI 2.39-181, p = 0.006, respectively). Grade 4 neutropenia and thrombocytopenia occurred in 17 patients each (94%), but there were no grade 4 nonhematopoietic adverse events. The modified Bonn protocol resulted in relatively favorable response and survival, and provided clinical benefits to patients with good PS, in particular. This study demonstrated that the modified Bonn protocol could be a feasible and encouraging treatment approach for lymphoma with CNS and systemic involvement.
Collapse
Affiliation(s)
- Kento Umino
- Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
365
|
Kerbauy MN, Moraes FY, Lok BH, Ma J, Kerbauy LN, Spratt DE, Santos FPS, Perini GF, Berlin A, Chung C, Hamerschlak N, Yahalom J. Challenges and opportunities in primary CNS lymphoma: A systematic review. Radiother Oncol 2017; 122:352-361. [PMID: 28104300 DOI: 10.1016/j.radonc.2016.12.033] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2016] [Revised: 12/29/2016] [Accepted: 12/29/2016] [Indexed: 12/31/2022]
Abstract
BACKGROUND Historically, high-dose methotrexate (HD-MTX) plus consolidation chemotherapy and/or whole brain radiotherapy (WBRT) has been the gold standard on Primary Central Nervous System Lymphoma (PCNSL) management. We sought to examine and summarize the data, on clinical trial (CT) setting, investigating multi-modality treatment to PCNSL. METHODS We performed a systematic review of electronic databases (Medline, EMBASE, Cochrane Database and clinicaltrials.gov) and a manual search to identify original PCNSL phase 2 and phase 3 CT from the last 10years. After a 4stage Prisma based selection process, 32 published (3 Randomized CT and 29 phases 2 CT) studies ultimately were selected for review. Four ongoing clinical trials found on clinicaltrial.gov were reviewed. Two investigators reviewed titles, abstracts, and articles independently. Two investigators abstracted data sequentially and evaluated each study independently. FINDINGS Treatment of PCNSL requires a multidisciplinary approach. HD-MTX represents the most accepted standard of care induction therapy for newly diagnosed PCNSL. When HD-MTX is given with WBRT for consolidation delayed neurotoxicity can be an important complication, particularly in elderly patients. Studies have suggested that WBRT may be deferred until relapse without compromising survival and deferring WBRT may be the best approach in elderly patients. Results from dose-reduced WBRT and consolidative HD-Ara-C are encouraging. High-dose chemotherapy in combination with autologous stem cell transplantation (HDC-ASCT) as chemotherapy alone has emerged as an important consolidative treatment for selected population. The optimal salvage therapy is still to be defined. CONCLUSION WBRT for consolidation is a well-studied modality; however emerging options to selected population such as HDC-ASCT, dose-reduced WBRT or chemotherapy alone are associated with similar survival outcome and less neurotoxicity in selected series. Ongoing and future clinical trials will better define the best approach on this rare disease.
Collapse
Affiliation(s)
- Mariana N Kerbauy
- Department of Hematology, Hospital Israelita Albert Einstein, São Paulo, Brazil
| | - Fabio Y Moraes
- Department of Radiation Oncology, Hospital Sírio-Libanês, São Paulo, Brazil; Department of Radiation Oncology, University of Toronto, Canada; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
| | - Benjamin H Lok
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA
| | - Jennifer Ma
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA
| | - Lucila N Kerbauy
- Department of Hematology, Hospital Israelita Albert Einstein, São Paulo, Brazil
| | - Daniel E Spratt
- Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, USA
| | - Fabio P S Santos
- Department of Hematology, Hospital Israelita Albert Einstein, São Paulo, Brazil
| | - Guilherme F Perini
- Department of Hematology, Hospital Israelita Albert Einstein, São Paulo, Brazil
| | - Alejandro Berlin
- Department of Radiation Oncology, University of Toronto, Canada; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
| | - Caroline Chung
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, USA
| | - Nelson Hamerschlak
- Department of Hematology, Hospital Israelita Albert Einstein, São Paulo, Brazil
| | - Joachim Yahalom
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA
| |
Collapse
|
366
|
Radiation Therapy in Primary Lymphoma of the CNS. Radiat Oncol 2017. [DOI: 10.1007/978-3-319-52619-5_9-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
367
|
Fossard G, Ferlay C, Nicolas-Virelizier E, Rey P, Ducray F, Jouanneau E, Faurie P, Belhabri A, Sunyack MP, Chassagne-Clément C, Thiesse P, Sebban C, Biron P, Blay JY, Ghesquières H. Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse. Eur J Cancer 2016; 72:12-19. [PMID: 28012348 DOI: 10.1016/j.ejca.2016.10.036] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2016] [Revised: 09/29/2016] [Accepted: 10/19/2016] [Indexed: 10/20/2022]
Abstract
BACKGROUND The optimal follow-up strategy for primary central nervous system lymphoma (PCNSL) patients after first-line therapy is unclear. The goal of this study is to determine the utility of planned brain surveillance imaging in the detection of relapse in a retrospective cohort of PCNSL patients. METHODS Patients were consecutive PCNSL cases treated in Leon Berard Cancer Centre, Lyon, France, from 1985 to 2011. Histology was diffuse large B-cell lymphoma in 94%. Patients were treated by methotrexate (92%) and cytarabine (63%) based-chemotherapy followed by radiotherapy for 108 patients (51%). Clinical records were reviewed for details at relapse and relationship to planned imaging. The imaging follow-up strategy was performed according to each treating physicians. RESULTS Among 209 PCNSL patients, 127 complete response patients entered in post-treatment observation and 63 (50%) subsequently relapsed. Among the 125 evaluable patients, the majority of relapses (N = 49, 80%) was asymptomatic and identified before the planned brain imaging. Surveillance imaging detected relapses before symptoms in 12 patients who entered in post-therapy observation (10%). The median number of brain imaging during the follow-up was 7 (0-13). A total of 819 MRI/CT-scan were performed leading to the detection of 12 asymptomatic relapses. The one year OS rates were 41% and 58% for symptomatic and non-symptomatic relapses, respectively (P = 0.21). CONCLUSION The majority of PCNSL relapses occurred outside planned follow-up with no difference in patient outcome between symptomatic and asymptomatic relapses. The role of brain imaging for the detection of relapses in the follow-up of PCNSL patients remains to be clarified.
Collapse
Affiliation(s)
- Gaëlle Fossard
- Centre Léon Bérard, Department of Hematology, Université Claude Bernard Lyon 1, Lyon, France
| | - Céline Ferlay
- Centre Léon Bérard, Department of Statistics, Université Claude Bernard Lyon 1, Lyon, France
| | | | - Philippe Rey
- Centre Léon Bérard, Department of Hematology, Université Claude Bernard Lyon 1, Lyon, France
| | - François Ducray
- Hopital Neurologique, Department of Neurology, Université Claude Bernard Lyon 1, Bron, France
| | - Emmanuel Jouanneau
- Hopital Neurologique, Department of Neurosurgery, Université Claude Bernard Lyon 1, Bron, France
| | - Pierre Faurie
- Centre Léon Bérard, Department of Hematology, Université Claude Bernard Lyon 1, Lyon, France
| | - Amine Belhabri
- Centre Léon Bérard, Department of Hematology, Université Claude Bernard Lyon 1, Lyon, France
| | - Marie-Pierre Sunyack
- Centre Léon Bérard, Department of Radiotherapy, Université Claude Bernard Lyon 1, Lyon, France
| | | | - Philippe Thiesse
- Centre Léon Bérard, Department of Radiology, Université Claude Bernard Lyon 1, Lyon, France
| | - Catherine Sebban
- Centre Léon Bérard, Department of Hematology, Université Claude Bernard Lyon 1, Lyon, France
| | - Pierre Biron
- Centre Léon Bérard, Department of Hematology, Université Claude Bernard Lyon 1, Lyon, France
| | - Jean-Yves Blay
- Centre Léon Bérard, Department of Hematology, Université Claude Bernard Lyon 1, Lyon, France
| | - Hervé Ghesquières
- Centre Léon Bérard, Department of Hematology, Université Claude Bernard Lyon 1, Lyon, France; Department of Hematology, Centre Hospitalier Lyon Sud, Université Claude Bernard Lyon 1, Pierre-Bénite, France.
| |
Collapse
|
368
|
Cerebrospinal Fluid IL-10 and IL-10/IL-6 as Accurate Diagnostic Biomarkers for Primary Central Nervous System Large B-cell Lymphoma. Sci Rep 2016; 6:38671. [PMID: 27924864 PMCID: PMC5141427 DOI: 10.1038/srep38671] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2016] [Accepted: 11/11/2016] [Indexed: 01/17/2023] Open
Abstract
Early diagnosis of primary central nervous system lymphoma (PCNSL) represents a challenge, and cerebrospinal fluid (CSF) cytokines may be diagnostic biomarkers for PCNSL. We used an electrochemiluminescence immunoassay to measure interleukin (IL)-10, IL-6, IL-8 and tumor necrosis factor α (TNF-α) in the CSF of 22 B cell PCNSL patients and 80 patients with other CNS diseases. CSF IL-10 was significantly higher in PCNSL patients than in the control group (median 74.7 pg/ml vs < 5.0 pg/ml, P < 0.000). Using a CSF IL-10 cutoff value of 8.2 pg/ml, the diagnostic sensitivity and specificity were 95.5% and 96.1%, respectively (AUC, 0.957; 95% CI, 0.901-1.000). For a CSF IL-10/IL-6 cutoff value of 0.72, the sensitivity was 95.5%, and the specificity was 100.0% (AUC, 0.976; 95% CI, 0.929-1.000). An increased CSF IL-10 level at diagnosis and post-treatment was associated with poor Progression free survival (PFS) for patients with PCNSL (P = 0.0181 and P = 0.0002, respectively). A low diagnostic value for PCNSL was found with CSF IL-8 or TNF-α. In conclusion, increased CSF IL-10 was a reliable diagnostic biomarker for large B cell PCNSL, and an IL-10/IL-6 ratio facilitates differentiation from other conditions, especially a CNS infection.
Collapse
|
369
|
Zhang Y, Dodson KH, Fischer R, Wang R, Li D, Sappington RM, Xu YQ. Probing electrical signals in the retina via graphene-integrated microfluidic platforms. NANOSCALE 2016; 8:19043-19049. [PMID: 27812594 PMCID: PMC5115917 DOI: 10.1039/c6nr07290a] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Graphene has attracted extensive attention in biological and biomedical fields due to its unique physical properties and excellent biocompatibility. We combine graphene field-effect transistors and scanning photocurrent microscopy with microfluidic platforms to investigate electrical signals in mouse retina. Remarkable photocurrent signals were detected from the graphene underneath the optic nerve head (ONH) of the retina, where the electrical activity from this region can modulate the carrier concentration of the graphene and induce local potential gradients. These built-in electrical potential gradients can efficiently separate photo-excited electron-hole pairs, leading to strong photocurrent responses in the graphene underneath the ONH. We also show that no significant photocurrent signal was observed in the graphene underneath either dehydrated or fixed retinal tissues, verifying that the photocurrent responses generated in the graphene underneath the ONH were indeed induced by the electrical activity in living retina. This method not only provides a way to investigate electrical processes in living retinal tissues, but also offers opportunities to study many other cellular systems involving cell-cell interactions through electrical signaling.
Collapse
Affiliation(s)
- Yuchen Zhang
- Department of Electrical Engineering and Computer Science, Vanderbilt University, Nashville, TN, USA
| | - Kirsten H. Dodson
- Department of Mechanical Engineering, Vanderbilt University, Nashville, TN, USA
| | - Rachel Fischer
- Department of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, USA
- Department of Pharmacology, Vanderbilt University School of Medicine, Vanderbilt University, Nashville, TN, USA
| | - Rui Wang
- Department of Physics and Astronomy, Vanderbilt University, Nashville, TN, USA
| | - Deyu Li
- Department of Mechanical Engineering, Vanderbilt University, Nashville, TN, USA
| | - Rebecca M. Sappington
- Department of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, USA
- Department of Pharmacology, Vanderbilt University School of Medicine, Vanderbilt University, Nashville, TN, USA
| | - Ya-Qiong Xu
- Department of Electrical Engineering and Computer Science, Vanderbilt University, Nashville, TN, USA
- Department of Physics and Astronomy, Vanderbilt University, Nashville, TN, USA
| |
Collapse
|
370
|
Batchelor TT. Primary central nervous system lymphoma. HEMATOLOGY. AMERICAN SOCIETY OF HEMATOLOGY. EDUCATION PROGRAM 2016; 2016:379-385. [PMID: 27913504 PMCID: PMC6142465 DOI: 10.1182/asheducation-2016.1.379] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Primary central nervous system lymphoma (PCNSL) is an extranodal non-Hodgkin lymphoma (NHL) confined to the brain, leptomeninges, eyes, or spinal cord. The majority of PCNSL cases occur in the immunocompetent host, the focus of this review. The prognosis of PCNSL is inferior to that of other NHL subtypes including other organ-specific subtypes of extranodal NHL. The 5- and 10-year survival proportions for PCNSL are 29.3% and 21.6%, respectively. The diagnosis and management of PCNSL differs from that of other primary brain cancers and NHL in other parts of the body.
Collapse
Affiliation(s)
- Tracy T Batchelor
- Departments of Neurology and Radiation Oncology, Division of Hematology/Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA
| |
Collapse
|
371
|
Chamoun K, Choquet S, Boyle E, Houillier C, Larrieu-Ciron D, Al Jijakli A, Delrieu V, Delwail V, Morschhauser F, Hoang-Xuan K, Soussain C. Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series. Neurology 2016; 88:101-102. [DOI: 10.1212/wnl.0000000000003420] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2016] [Accepted: 09/21/2016] [Indexed: 11/15/2022] Open
|
372
|
High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia 2016; 31:846-852. [PMID: 27843136 PMCID: PMC5383936 DOI: 10.1038/leu.2016.334] [Citation(s) in RCA: 111] [Impact Index Per Article: 13.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2016] [Revised: 10/10/2016] [Accepted: 10/21/2016] [Indexed: 01/12/2023]
Abstract
To investigate immuno-chemotherapy for elderly immuno-competent patients (⩾65 years) with newly diagnosed primary central nervous system lymphoma, we conducted a multicentre single-arm trial. One cycle consisted of rituximab (375 mg/m2, days 1, 15, 29), high-dose methotrexate (3 g/m2 days 2, 16, 30), procarbazine (60 mg/m2 days 2–11) and lomustine (110 mg/m2, day 2)—R-MPL protocol. Owing to infectious complications, we omitted lomustine during the study and consecutive patients were treated with the R-MP protocol. Three cycles were scheduled and repeated on day 43. Subsequently, patients commenced 4 weekly maintenance treatment with procarbazine (100 mg for 5 days). Primary end point was complete remission (CR) after 3 cycles. We included 107 patients (69 treated with R-MPL and 38 with R-MP). In all, 38/107 patients achieved CR (35.5%) and 15 (14.0%) achieved partial remission. R-MP was associated with a lower CR rate (31.6%) compared with R-MPL (37.7%), but respective 2-year progression-free survival (All 37.3% R-MP 34.9% R-MPL 38.8%) and overall survival (All 47.0% R-MP 47.7% R-MPL 46.0%) rates were similar. R-MP was associated with less ⩾grade 3 toxicities compared with R-MPL (71.1% vs 87.0%). R-MP is more feasible while still associated with similar efficacy compared with R-MPL and warrants further improvement in future studies.
Collapse
|
373
|
Korfel A, Nowosielski M, Pardo-Moreno J, Penalver FJ, Buda G, Bennani H, Costopoulos M, Le Garff-Tavernier M, Soussain C, Schmid M, Orfao JA, Glantz M. How to facilitate early diagnosis of CNS involvement in malignant lymphoma. Expert Rev Hematol 2016; 9:1081-1091. [PMID: 27677656 DOI: 10.1080/17474086.2016.1242405] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
INTRODUCTION Making the diagnosis of secondary CNS involvement in lymphoma can be difficult due to unspecific signs and symptoms, limited accessibility of brain/myelon parenchyma and low sensitivity and/or specifity of imaging and cerebrospinal fluid (CSF) examination currently available. Areas covered: MRI of the total neuroaxis followed by CSF cytomorphology and flow cytometry are methods of choice when CNS lymphoma (CNSL) is suspected. To reduce the numerous pitfalls of these examinations several aspects should be considered. New CSF biomarkers might be of potential diagnostic value. Attempts to standardize response criteria are presented. Expert commentary: Diagnosing CNSL remains challenging. Until diagnostic methods combining high sensitivity with high specifity are routinely introduced, high level of awareness and optimal utilization of examinations currently available are needed to early diagnose this potentially devastating disease.
Collapse
Affiliation(s)
- Agnieszka Korfel
- a Department of Hematology, Oncology and Tumor Immunology , Charite University Medicine Berlin , Berlin , Germany
| | - Martha Nowosielski
- b Department of Neurology , Medical University Innsbruck , Innsbruck , Austria
| | - Javier Pardo-Moreno
- c Department of Neurology , University Hospital King Juan Carlos , Madrid , Spain
| | | | - Gabriele Buda
- e Department of Hematology and Oncology , University of Pisa , Pisa , Italy
| | - Hind Bennani
- f Department of Biology , Hôpital Foch , Suresnes , France
| | - Myrto Costopoulos
- g Department of Biological Hematology , Pitie Salpetriere Hospital , Paris , France
| | | | - Carole Soussain
- h Department of Hematology , Institut Curie - Hôpital René Huguenin , Paris , France
| | - Mathias Schmid
- i Department of Hematology and Oncology , Stadtspital Triemli Zürich , Zürich , Switzerland
| | - Jose Alberto Orfao
- j Department of Medicine and Cytometry Service , University of Salamanca , Salamanca , Spain
| | | |
Collapse
|
374
|
Peñalver FJ, Sancho JM, de la Fuente A, Olave MT, Martín A, Panizo C, Pérez E, Salar A, Orfao A. Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO). Haematologica 2016; 102:235-245. [PMID: 27846613 DOI: 10.3324/haematol.2016.149120] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2016] [Accepted: 10/07/2016] [Indexed: 02/01/2023] Open
Abstract
Diffuse large B-cell lymphoma patients have a 5% overall risk of central nervous system events (relapse or progression), which account for high morbidity and frequently fatal outcomes,1 and shortened overall survival of <6 months.2 Early diagnosis of central nervous system events is critical for successful treatment and improved prognosis. Identification of patients at risk of central nervous system disease is critical to accurately identify candidates for central nervous system prophylaxis vs. THERAPY 3-5 This report by the Spanish Lymphoma Group (GELTAMO) aims to provide useful guidelines and recommendations for the prevention, diagnosis, and treatment of central nervous system diffuse large B-cell lymphoma patients with, or at risk of, leptomeningeal and/or brain parenchyma lymphoma relapse. A panel of lymphoma experts working on behalf of GELTAMO reviewed all data published on these topics available in PubMed up to May 2016. Recommendations were classified according to the Grading of Recommendations Assessment Development and Evaluation (GRADE) approach.6 A practical algorithm based on the proposed recommendations was then developed (Figure 1). Initial discussions among experts were held in May 2014, and final consensus was reached in June 2016. The final manuscript was reviewed by all authors and the Scientific Committee of GELTAMO.
Collapse
Affiliation(s)
| | - Juan-Manuel Sancho
- Clinical Hematology Department, ICO-IJC Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
| | | | - María-Teresa Olave
- Department of Hematology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
| | - Alejandro Martín
- Department of Hematology, Hospital Universitario de Salamanca, Department of Medicine, Cytometry Service (NUCLEUS) and Cancer Research Center (IBMCC-USAL-CSIC) and IBSAL, University of Salamanca, Pamplona, Spain
| | - Carlos Panizo
- Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain
| | - Elena Pérez
- Department of Hematology, Hospital General Universitario Morales Meseguer, Murcia, Spain
| | - Antonio Salar
- Department of Hematology, Hospital del Mar, Barcelona, Spain
| | - Alberto Orfao
- Department of Hematology, Hospital Universitario de Salamanca, Department of Medicine, Cytometry Service (NUCLEUS) and Cancer Research Center (IBMCC-USAL-CSIC) and IBSAL, University of Salamanca, Pamplona, Spain
| | | |
Collapse
|
375
|
Kuitunen H, Tokola S, Siniluoto T, Isokangas M, Sonkajärvi E, Alahuhta S, Turpeenniemi-Hujanen T, Jantunen E, Nousiainen T, Vasala K, Kuittinen O. Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL). J Neurooncol 2016; 131:293-300. [DOI: 10.1007/s11060-016-2293-8] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2016] [Accepted: 10/09/2016] [Indexed: 11/29/2022]
|
376
|
Scordo M, Bhatt V, Hsu M, Omuro AM, Matasar MJ, DeAngelis LM, Dahi PB, Moskowitz CH, Giralt SA, Sauter CS. A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. Biol Blood Marrow Transplant 2016; 23:38-43. [PMID: 27713090 DOI: 10.1016/j.bbmt.2016.09.024] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2016] [Accepted: 09/30/2016] [Indexed: 11/17/2022]
Abstract
High-dose therapy and autologous stem cell transplantation (ASCT) with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning has emerged as an effective postinduction treatment strategy for patients with primary central nervous system lymphoma (PCNSL) or secondary central nervous system lymphoma (SCNSL), but it is associated with considerable toxicity and transplantation-related mortality (TRM) in the modern era. Forty-three adult patients with chemosensitive PCNSL or SCNSL underwent TBC-conditioned ASCT between 2006 and 2015. Twenty-eight of these patients received pharmacokinetically (PK)-targeted busulfan dosing. The median number of clinically relevant individual grade ≥3 nonhematologic toxicities per patient was 5. We found no association between pretransplantation patient characteristics and the presence of more than 5 grade ≥3 nonhematologic toxicities. Patients with elevated first-dose busulfan area under the curve values did not experience more toxicity. Paradoxically, patients treated with more than 2 regimens before undergoing ASCT had lower first-dose busulfan AUC values. With a median follow-up among survivors of 20 months, 1-year progression-free survival (PFS) and overall survival (OS) from the time of ASCT were 83% and 87%, respectively. Although this study reaffirms the favorable PFS and OS associated with TBC-conditioned ASCT for PCNSL or SCNSL, this treatment strategy carries a large toxicity burden.
Collapse
Affiliation(s)
- Michael Scordo
- Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York.
| | - Valkal Bhatt
- Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Meier Hsu
- Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Antonio M Omuro
- Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Neurology, Weill Cornell Medical College, New York, New York
| | - Matthew J Matasar
- Department of Medicine, Lymphoma Service, Adult BMT Service, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York
| | - Lisa M DeAngelis
- Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Neurology, Weill Cornell Medical College, New York, New York
| | - Parastoo B Dahi
- Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York
| | - Craig H Moskowitz
- Department of Medicine, Lymphoma Service, Adult BMT Service, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York
| | - Sergio A Giralt
- Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York
| | - Craig S Sauter
- Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York
| |
Collapse
|
377
|
Boros A, Michot JM, Hoang-Xuan K, Mazeron R. [Role of radiotherapy in the treatment of NK/T-cell nasal type and primary cerebral lymphomas]. Cancer Radiother 2016; 20:535-42. [PMID: 27614517 DOI: 10.1016/j.canrad.2016.07.078] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2016] [Accepted: 07/22/2016] [Indexed: 01/28/2023]
Abstract
The head and neck are common sites for extranodal non-Hodgkin lymphomas. Radiotherapy plays an important role in the treatment of low-grade lymphomas, with curative or palliative intent. In the case of high-grade lymphomas, its combination with chemotherapy is debated. Its role is however undeniable in two specific entities: NK/T-cell lymphoma NK/T nasal type, and primary central nervous system lymphomas, which are the subject of this review.
Collapse
Affiliation(s)
- A Boros
- Département d'oncologie radiothérapie, Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France; Université Paris Saclay, 15, rue Georges-Clemenceau, 91400 Orsay, France
| | - J-M Michot
- Université Paris Saclay, 15, rue Georges-Clemenceau, 91400 Orsay, France; Département d'innovation thérapeutique et d'essais précoces, Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France
| | - K Hoang-Xuan
- Département de neurologie, division Mazarin, centre hospitalier universitaire Pitié-Salpêtrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France; Université Pierre-et-Marie-Curie, 4, place Jussieu, 75005 Paris, France; Institut du cerveau et de la moelle, CNRS UMR 7225, Inserm U 1127, 47-83, boulevard de l'Hôpital, 75013 Paris, France; Réseau lymphomes oculocérébraux (LOC), 47-83, boulevard de l'Hôpital, 75013 Paris, France
| | - R Mazeron
- Département d'oncologie radiothérapie, Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France; Université Paris Saclay, 15, rue Georges-Clemenceau, 91400 Orsay, France.
| |
Collapse
|
378
|
Vitolo U, Seymour J, Martelli M, Illerhaus G, Illidge T, Zucca E, Campo E, Ladetto M. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27:v91-v102. [DOI: 10.1093/annonc/mdw175] [Citation(s) in RCA: 73] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
|
379
|
Cheah CY, Bröckelmann PJ, Chihara D, Moskowitz AJ, Engert A, Jerkeman M, El-Galaly TC, Augustson B, Vose J, Bartlett NL, Villa D, Connors JM, Feldman T, Pinnix CC, Milgrom SA, Dabaja B, Oki Y, Fanale MA. Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. Am J Hematol 2016; 91:894-9. [PMID: 27222367 DOI: 10.1002/ajh.24429] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2016] [Revised: 05/20/2016] [Accepted: 05/22/2016] [Indexed: 12/21/2022]
Abstract
Central nervous system (CNS) involvement is rare in patients with Hodgkin lymphoma (HL). Thus, the clinical features and outcomes are not well described. Cases of histologically confirmed CNS HL diagnosed between 1995 and 2015 were retrospectively identified in institutional (n = 7), national (n = 2), and cooperative group (n = 1) databases. We screened 30,781 patients with HL in our combined databases and identified 21 patients meeting eligibility criteria, an estimated frequency of 0.07%. CNS involvement was present at initial diagnosis in 10 patients (48%) and a feature of relapsed/refractory disease in 11 (52%). Among these 11 patients, the median time from initial diagnosis of HL to development of CNS involvement was 1.9 years (range 0.4-6.6) and the median number of prior lines of therapy was 2 (range 1-7). Altogether, treatments included radiation, multiagent systemic chemotherapy, combined modality therapy, and subtotal resection. The overall response rate was 65%. After a median follow-up of 3.6 years (range 0.8-13.2) from diagnosis of CNS HL, the median PFS and OS were 7.6 and 29 months, respectively. CNS involvement as a feature of relapsed/refractory disease was adversely prognostic for both PFS and OS; however, four patients remain alive and free of relapse at 7-78 months follow-up. CNS involvement in HL is exceedingly rare and has a distinct clinical presentation with predilection for parenchymal lesions with dural extension. Around one-quarter of patients, mostly with CNS involvement at initial HL diagnosis, experience prolonged disease-free survival. Am. J. Hematol. 91:894-899, 2016. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Chan Y. Cheah
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston Texas
- Department of Haematology; Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine WA; Perth Western Australia Australia
- University of Western Australia; Crawley Western Australia Australia
| | - Paul J. Bröckelmann
- Department of Internal Medicine and German Hodgkin Study Group; University Hospital of Cologne; Cologne Germany
- Lymphoma Service; Memorial Sloan Kettering Cancer Center; New York New York
| | - Dai Chihara
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston Texas
| | | | - Andreas Engert
- Department of Internal Medicine and German Hodgkin Study Group; University Hospital of Cologne; Cologne Germany
| | - Mats Jerkeman
- Department of Oncology; Lund University; Lund Sweden
| | | | - Bradley Augustson
- Department of Haematology; Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine WA; Perth Western Australia Australia
- University of Western Australia; Crawley Western Australia Australia
| | - Julie Vose
- Department of Hematology/Oncology; University of Nebraska Medical Center; Omaha Nebraska
| | | | - Diego Villa
- British Columbia Cancer Agency Centre for Lymphoid Cancer; Vancouver British Columbia Canada
| | - Joseph M. Connors
- British Columbia Cancer Agency Centre for Lymphoid Cancer; Vancouver British Columbia Canada
| | - Tatyana Feldman
- Department of Hematology; Hackensack University Cancer Center; Hackensack New Jersey
| | - Chelsea C. Pinnix
- Department of Radiation Oncology; University of Texas MD Anderson Cancer Center; Houston Texas
| | - Sarah A. Milgrom
- Department of Radiation Oncology; University of Texas MD Anderson Cancer Center; Houston Texas
| | - Bouthaina Dabaja
- Department of Radiation Oncology; University of Texas MD Anderson Cancer Center; Houston Texas
| | - Yasuhiro Oki
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston Texas
| | - Michelle A. Fanale
- Department of Lymphoma/Myeloma; University of Texas MD Anderson Cancer Center; Houston Texas
| |
Collapse
|
380
|
Gupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DI, Hwang J, Kaplan LD, Luce JA, Volberding P, Treseler PA, Rubenstein JL. Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro Oncol 2016; 19:99-108. [PMID: 27576871 DOI: 10.1093/neuonc/now155] [Citation(s) in RCA: 43] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND The optimal therapeutic approach for patients with AIDS-related primary central nervous system lymphoma (AR-PCNSL) remains undefined. While its incidence declined substantially with combination antiretroviral therapy (cART), AR-PCNSL remains a highly aggressive neoplasm for which whole brain radiotherapy (WBRT) is considered a standard first-line intervention. METHODS To identify therapy-related factors associated with favorable survival, we first retrospectively analyzed outcomes of AR-PCNSL patients treated at San Francisco General Hospital, a public hospital with a long history of dedicated care for patients with HIV and AIDS-related malignancies. Results were validated in a retrospective, multicenter analysis that evaluated all newly diagnosed patients with AR-PCNSL treated with cART plus high-dose methotrexate (HD-MTX). RESULTS We provide evidence that CD4+ reconstitution with cART administered during HD-MTX correlates with long-term survival among patients with CD4 <100. This was confirmed in a multicenter analysis which demonstrated that integration of cART regimens with HD-MTX was generally well tolerated and resulted in longer progression-free survival than other treatments. No profound differences in immunophenotype were identified in an analysis of AR-PCNSL tumors that arose in the pre- versus post-cART eras. However, we detected evidence for a demographic shift, as the proportion of minority patients with AR-PCNSL increased since advent of cART. CONCLUSION Long-term disease-free survival can be achieved in AR-PCNSL, even among those with histories of opportunistic infections, limited access to health care, and medical non-adherence. Given this, as well as the long-term toxicities of WBRT, we recommend that integration of cART plus first-line HD-MTX be considered for all patients with AR-PCNSL.
Collapse
Affiliation(s)
- Neel K Gupta
- Division of Hematology/Oncology, University of California, San Francisco (N.K.G., C.W., G.M., D.I.A., L.D.K., J.A.L., P.V., J.L.R.); Department of Pathology, University of California, San Francisco (A.N., P.A.T.); Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY (A.O.); Division of Hematology/Oncology, University of California, San Diego (E.G.R.); Division of Hematology/Oncology, San Francisco General Hospital (C.W., D.I.A., J.A.L.); Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL (M.J., J.C.C.); Department of Medicine, Section of Hematology/Oncology, John H. Stroger Jr. Hospital of Cook County, Ruth M. Rothstein CORE Center, Developmental Center for AIDS Research, Chicago, IL (P.G.R.); Department of Internal Medicine, Rush University Medical Center, Chicago, IL (P.G.R.); UCSF Cancer Registry, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (A.G.); Helen Diller Family Comprehensive Cancer Center, University of California San Francisco (D.I.A., J.H., L.D.K., J.A.L., P.V., P.A.T., J.L.R.); Biostatistics and Computational Biology Core, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (J.H.); Center for AIDS Research; UCSF Gladstone Institute of Virology and Immunology (P.V.)
| | - Amber Nolan
- Division of Hematology/Oncology, University of California, San Francisco (N.K.G., C.W., G.M., D.I.A., L.D.K., J.A.L., P.V., J.L.R.); Department of Pathology, University of California, San Francisco (A.N., P.A.T.); Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY (A.O.); Division of Hematology/Oncology, University of California, San Diego (E.G.R.); Division of Hematology/Oncology, San Francisco General Hospital (C.W., D.I.A., J.A.L.); Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL (M.J., J.C.C.); Department of Medicine, Section of Hematology/Oncology, John H. Stroger Jr. Hospital of Cook County, Ruth M. Rothstein CORE Center, Developmental Center for AIDS Research, Chicago, IL (P.G.R.); Department of Internal Medicine, Rush University Medical Center, Chicago, IL (P.G.R.); UCSF Cancer Registry, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (A.G.); Helen Diller Family Comprehensive Cancer Center, University of California San Francisco (D.I.A., J.H., L.D.K., J.A.L., P.V., P.A.T., J.L.R.); Biostatistics and Computational Biology Core, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (J.H.); Center for AIDS Research; UCSF Gladstone Institute of Virology and Immunology (P.V.)
| | - Antonio Omuro
- Division of Hematology/Oncology, University of California, San Francisco (N.K.G., C.W., G.M., D.I.A., L.D.K., J.A.L., P.V., J.L.R.); Department of Pathology, University of California, San Francisco (A.N., P.A.T.); Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY (A.O.); Division of Hematology/Oncology, University of California, San Diego (E.G.R.); Division of Hematology/Oncology, San Francisco General Hospital (C.W., D.I.A., J.A.L.); Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL (M.J., J.C.C.); Department of Medicine, Section of Hematology/Oncology, John H. Stroger Jr. Hospital of Cook County, Ruth M. Rothstein CORE Center, Developmental Center for AIDS Research, Chicago, IL (P.G.R.); Department of Internal Medicine, Rush University Medical Center, Chicago, IL (P.G.R.); UCSF Cancer Registry, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (A.G.); Helen Diller Family Comprehensive Cancer Center, University of California San Francisco (D.I.A., J.H., L.D.K., J.A.L., P.V., P.A.T., J.L.R.); Biostatistics and Computational Biology Core, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (J.H.); Center for AIDS Research; UCSF Gladstone Institute of Virology and Immunology (P.V.)
| | - Erin G Reid
- Division of Hematology/Oncology, University of California, San Francisco (N.K.G., C.W., G.M., D.I.A., L.D.K., J.A.L., P.V., J.L.R.); Department of Pathology, University of California, San Francisco (A.N., P.A.T.); Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY (A.O.); Division of Hematology/Oncology, University of California, San Diego (E.G.R.); Division of Hematology/Oncology, San Francisco General Hospital (C.W., D.I.A., J.A.L.); Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL (M.J., J.C.C.); Department of Medicine, Section of Hematology/Oncology, John H. Stroger Jr. Hospital of Cook County, Ruth M. Rothstein CORE Center, Developmental Center for AIDS Research, Chicago, IL (P.G.R.); Department of Internal Medicine, Rush University Medical Center, Chicago, IL (P.G.R.); UCSF Cancer Registry, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (A.G.); Helen Diller Family Comprehensive Cancer Center, University of California San Francisco (D.I.A., J.H., L.D.K., J.A.L., P.V., P.A.T., J.L.R.); Biostatistics and Computational Biology Core, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (J.H.); Center for AIDS Research; UCSF Gladstone Institute of Virology and Immunology (P.V.)
| | - Chia-Ching Wang
- Division of Hematology/Oncology, University of California, San Francisco (N.K.G., C.W., G.M., D.I.A., L.D.K., J.A.L., P.V., J.L.R.); Department of Pathology, University of California, San Francisco (A.N., P.A.T.); Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY (A.O.); Division of Hematology/Oncology, University of California, San Diego (E.G.R.); Division of Hematology/Oncology, San Francisco General Hospital (C.W., D.I.A., J.A.L.); Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL (M.J., J.C.C.); Department of Medicine, Section of Hematology/Oncology, John H. Stroger Jr. Hospital of Cook County, Ruth M. Rothstein CORE Center, Developmental Center for AIDS Research, Chicago, IL (P.G.R.); Department of Internal Medicine, Rush University Medical Center, Chicago, IL (P.G.R.); UCSF Cancer Registry, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (A.G.); Helen Diller Family Comprehensive Cancer Center, University of California San Francisco (D.I.A., J.H., L.D.K., J.A.L., P.V., P.A.T., J.L.R.); Biostatistics and Computational Biology Core, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (J.H.); Center for AIDS Research; UCSF Gladstone Institute of Virology and Immunology (P.V.)
| | - Gabriel Mannis
- Division of Hematology/Oncology, University of California, San Francisco (N.K.G., C.W., G.M., D.I.A., L.D.K., J.A.L., P.V., J.L.R.); Department of Pathology, University of California, San Francisco (A.N., P.A.T.); Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY (A.O.); Division of Hematology/Oncology, University of California, San Diego (E.G.R.); Division of Hematology/Oncology, San Francisco General Hospital (C.W., D.I.A., J.A.L.); Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL (M.J., J.C.C.); Department of Medicine, Section of Hematology/Oncology, John H. Stroger Jr. Hospital of Cook County, Ruth M. Rothstein CORE Center, Developmental Center for AIDS Research, Chicago, IL (P.G.R.); Department of Internal Medicine, Rush University Medical Center, Chicago, IL (P.G.R.); UCSF Cancer Registry, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (A.G.); Helen Diller Family Comprehensive Cancer Center, University of California San Francisco (D.I.A., J.H., L.D.K., J.A.L., P.V., P.A.T., J.L.R.); Biostatistics and Computational Biology Core, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (J.H.); Center for AIDS Research; UCSF Gladstone Institute of Virology and Immunology (P.V.)
| | - Michael Jaglal
- Division of Hematology/Oncology, University of California, San Francisco (N.K.G., C.W., G.M., D.I.A., L.D.K., J.A.L., P.V., J.L.R.); Department of Pathology, University of California, San Francisco (A.N., P.A.T.); Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY (A.O.); Division of Hematology/Oncology, University of California, San Diego (E.G.R.); Division of Hematology/Oncology, San Francisco General Hospital (C.W., D.I.A., J.A.L.); Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL (M.J., J.C.C.); Department of Medicine, Section of Hematology/Oncology, John H. Stroger Jr. Hospital of Cook County, Ruth M. Rothstein CORE Center, Developmental Center for AIDS Research, Chicago, IL (P.G.R.); Department of Internal Medicine, Rush University Medical Center, Chicago, IL (P.G.R.); UCSF Cancer Registry, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (A.G.); Helen Diller Family Comprehensive Cancer Center, University of California San Francisco (D.I.A., J.H., L.D.K., J.A.L., P.V., P.A.T., J.L.R.); Biostatistics and Computational Biology Core, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (J.H.); Center for AIDS Research; UCSF Gladstone Institute of Virology and Immunology (P.V.)
| | - Julio C Chavez
- Division of Hematology/Oncology, University of California, San Francisco (N.K.G., C.W., G.M., D.I.A., L.D.K., J.A.L., P.V., J.L.R.); Department of Pathology, University of California, San Francisco (A.N., P.A.T.); Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY (A.O.); Division of Hematology/Oncology, University of California, San Diego (E.G.R.); Division of Hematology/Oncology, San Francisco General Hospital (C.W., D.I.A., J.A.L.); Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL (M.J., J.C.C.); Department of Medicine, Section of Hematology/Oncology, John H. Stroger Jr. Hospital of Cook County, Ruth M. Rothstein CORE Center, Developmental Center for AIDS Research, Chicago, IL (P.G.R.); Department of Internal Medicine, Rush University Medical Center, Chicago, IL (P.G.R.); UCSF Cancer Registry, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (A.G.); Helen Diller Family Comprehensive Cancer Center, University of California San Francisco (D.I.A., J.H., L.D.K., J.A.L., P.V., P.A.T., J.L.R.); Biostatistics and Computational Biology Core, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (J.H.); Center for AIDS Research; UCSF Gladstone Institute of Virology and Immunology (P.V.)
| | - Paul G Rubinstein
- Division of Hematology/Oncology, University of California, San Francisco (N.K.G., C.W., G.M., D.I.A., L.D.K., J.A.L., P.V., J.L.R.); Department of Pathology, University of California, San Francisco (A.N., P.A.T.); Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY (A.O.); Division of Hematology/Oncology, University of California, San Diego (E.G.R.); Division of Hematology/Oncology, San Francisco General Hospital (C.W., D.I.A., J.A.L.); Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL (M.J., J.C.C.); Department of Medicine, Section of Hematology/Oncology, John H. Stroger Jr. Hospital of Cook County, Ruth M. Rothstein CORE Center, Developmental Center for AIDS Research, Chicago, IL (P.G.R.); Department of Internal Medicine, Rush University Medical Center, Chicago, IL (P.G.R.); UCSF Cancer Registry, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (A.G.); Helen Diller Family Comprehensive Cancer Center, University of California San Francisco (D.I.A., J.H., L.D.K., J.A.L., P.V., P.A.T., J.L.R.); Biostatistics and Computational Biology Core, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (J.H.); Center for AIDS Research; UCSF Gladstone Institute of Virology and Immunology (P.V.)
| | - Ann Griffin
- Division of Hematology/Oncology, University of California, San Francisco (N.K.G., C.W., G.M., D.I.A., L.D.K., J.A.L., P.V., J.L.R.); Department of Pathology, University of California, San Francisco (A.N., P.A.T.); Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY (A.O.); Division of Hematology/Oncology, University of California, San Diego (E.G.R.); Division of Hematology/Oncology, San Francisco General Hospital (C.W., D.I.A., J.A.L.); Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL (M.J., J.C.C.); Department of Medicine, Section of Hematology/Oncology, John H. Stroger Jr. Hospital of Cook County, Ruth M. Rothstein CORE Center, Developmental Center for AIDS Research, Chicago, IL (P.G.R.); Department of Internal Medicine, Rush University Medical Center, Chicago, IL (P.G.R.); UCSF Cancer Registry, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (A.G.); Helen Diller Family Comprehensive Cancer Center, University of California San Francisco (D.I.A., J.H., L.D.K., J.A.L., P.V., P.A.T., J.L.R.); Biostatistics and Computational Biology Core, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (J.H.); Center for AIDS Research; UCSF Gladstone Institute of Virology and Immunology (P.V.)
| | - Donald I Abrams
- Division of Hematology/Oncology, University of California, San Francisco (N.K.G., C.W., G.M., D.I.A., L.D.K., J.A.L., P.V., J.L.R.); Department of Pathology, University of California, San Francisco (A.N., P.A.T.); Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY (A.O.); Division of Hematology/Oncology, University of California, San Diego (E.G.R.); Division of Hematology/Oncology, San Francisco General Hospital (C.W., D.I.A., J.A.L.); Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL (M.J., J.C.C.); Department of Medicine, Section of Hematology/Oncology, John H. Stroger Jr. Hospital of Cook County, Ruth M. Rothstein CORE Center, Developmental Center for AIDS Research, Chicago, IL (P.G.R.); Department of Internal Medicine, Rush University Medical Center, Chicago, IL (P.G.R.); UCSF Cancer Registry, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (A.G.); Helen Diller Family Comprehensive Cancer Center, University of California San Francisco (D.I.A., J.H., L.D.K., J.A.L., P.V., P.A.T., J.L.R.); Biostatistics and Computational Biology Core, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (J.H.); Center for AIDS Research; UCSF Gladstone Institute of Virology and Immunology (P.V.)
| | - Jimmy Hwang
- Division of Hematology/Oncology, University of California, San Francisco (N.K.G., C.W., G.M., D.I.A., L.D.K., J.A.L., P.V., J.L.R.); Department of Pathology, University of California, San Francisco (A.N., P.A.T.); Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY (A.O.); Division of Hematology/Oncology, University of California, San Diego (E.G.R.); Division of Hematology/Oncology, San Francisco General Hospital (C.W., D.I.A., J.A.L.); Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL (M.J., J.C.C.); Department of Medicine, Section of Hematology/Oncology, John H. Stroger Jr. Hospital of Cook County, Ruth M. Rothstein CORE Center, Developmental Center for AIDS Research, Chicago, IL (P.G.R.); Department of Internal Medicine, Rush University Medical Center, Chicago, IL (P.G.R.); UCSF Cancer Registry, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (A.G.); Helen Diller Family Comprehensive Cancer Center, University of California San Francisco (D.I.A., J.H., L.D.K., J.A.L., P.V., P.A.T., J.L.R.); Biostatistics and Computational Biology Core, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (J.H.); Center for AIDS Research; UCSF Gladstone Institute of Virology and Immunology (P.V.)
| | - Lawrence D Kaplan
- Division of Hematology/Oncology, University of California, San Francisco (N.K.G., C.W., G.M., D.I.A., L.D.K., J.A.L., P.V., J.L.R.); Department of Pathology, University of California, San Francisco (A.N., P.A.T.); Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY (A.O.); Division of Hematology/Oncology, University of California, San Diego (E.G.R.); Division of Hematology/Oncology, San Francisco General Hospital (C.W., D.I.A., J.A.L.); Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL (M.J., J.C.C.); Department of Medicine, Section of Hematology/Oncology, John H. Stroger Jr. Hospital of Cook County, Ruth M. Rothstein CORE Center, Developmental Center for AIDS Research, Chicago, IL (P.G.R.); Department of Internal Medicine, Rush University Medical Center, Chicago, IL (P.G.R.); UCSF Cancer Registry, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (A.G.); Helen Diller Family Comprehensive Cancer Center, University of California San Francisco (D.I.A., J.H., L.D.K., J.A.L., P.V., P.A.T., J.L.R.); Biostatistics and Computational Biology Core, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (J.H.); Center for AIDS Research; UCSF Gladstone Institute of Virology and Immunology (P.V.)
| | - Judith A Luce
- Division of Hematology/Oncology, University of California, San Francisco (N.K.G., C.W., G.M., D.I.A., L.D.K., J.A.L., P.V., J.L.R.); Department of Pathology, University of California, San Francisco (A.N., P.A.T.); Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY (A.O.); Division of Hematology/Oncology, University of California, San Diego (E.G.R.); Division of Hematology/Oncology, San Francisco General Hospital (C.W., D.I.A., J.A.L.); Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL (M.J., J.C.C.); Department of Medicine, Section of Hematology/Oncology, John H. Stroger Jr. Hospital of Cook County, Ruth M. Rothstein CORE Center, Developmental Center for AIDS Research, Chicago, IL (P.G.R.); Department of Internal Medicine, Rush University Medical Center, Chicago, IL (P.G.R.); UCSF Cancer Registry, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (A.G.); Helen Diller Family Comprehensive Cancer Center, University of California San Francisco (D.I.A., J.H., L.D.K., J.A.L., P.V., P.A.T., J.L.R.); Biostatistics and Computational Biology Core, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (J.H.); Center for AIDS Research; UCSF Gladstone Institute of Virology and Immunology (P.V.)
| | - Paul Volberding
- Division of Hematology/Oncology, University of California, San Francisco (N.K.G., C.W., G.M., D.I.A., L.D.K., J.A.L., P.V., J.L.R.); Department of Pathology, University of California, San Francisco (A.N., P.A.T.); Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY (A.O.); Division of Hematology/Oncology, University of California, San Diego (E.G.R.); Division of Hematology/Oncology, San Francisco General Hospital (C.W., D.I.A., J.A.L.); Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL (M.J., J.C.C.); Department of Medicine, Section of Hematology/Oncology, John H. Stroger Jr. Hospital of Cook County, Ruth M. Rothstein CORE Center, Developmental Center for AIDS Research, Chicago, IL (P.G.R.); Department of Internal Medicine, Rush University Medical Center, Chicago, IL (P.G.R.); UCSF Cancer Registry, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (A.G.); Helen Diller Family Comprehensive Cancer Center, University of California San Francisco (D.I.A., J.H., L.D.K., J.A.L., P.V., P.A.T., J.L.R.); Biostatistics and Computational Biology Core, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (J.H.); Center for AIDS Research; UCSF Gladstone Institute of Virology and Immunology (P.V.)
| | - Patrick A Treseler
- Division of Hematology/Oncology, University of California, San Francisco (N.K.G., C.W., G.M., D.I.A., L.D.K., J.A.L., P.V., J.L.R.); Department of Pathology, University of California, San Francisco (A.N., P.A.T.); Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY (A.O.); Division of Hematology/Oncology, University of California, San Diego (E.G.R.); Division of Hematology/Oncology, San Francisco General Hospital (C.W., D.I.A., J.A.L.); Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL (M.J., J.C.C.); Department of Medicine, Section of Hematology/Oncology, John H. Stroger Jr. Hospital of Cook County, Ruth M. Rothstein CORE Center, Developmental Center for AIDS Research, Chicago, IL (P.G.R.); Department of Internal Medicine, Rush University Medical Center, Chicago, IL (P.G.R.); UCSF Cancer Registry, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (A.G.); Helen Diller Family Comprehensive Cancer Center, University of California San Francisco (D.I.A., J.H., L.D.K., J.A.L., P.V., P.A.T., J.L.R.); Biostatistics and Computational Biology Core, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (J.H.); Center for AIDS Research; UCSF Gladstone Institute of Virology and Immunology (P.V.)
| | - James L Rubenstein
- Division of Hematology/Oncology, University of California, San Francisco (N.K.G., C.W., G.M., D.I.A., L.D.K., J.A.L., P.V., J.L.R.); Department of Pathology, University of California, San Francisco (A.N., P.A.T.); Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY (A.O.); Division of Hematology/Oncology, University of California, San Diego (E.G.R.); Division of Hematology/Oncology, San Francisco General Hospital (C.W., D.I.A., J.A.L.); Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL (M.J., J.C.C.); Department of Medicine, Section of Hematology/Oncology, John H. Stroger Jr. Hospital of Cook County, Ruth M. Rothstein CORE Center, Developmental Center for AIDS Research, Chicago, IL (P.G.R.); Department of Internal Medicine, Rush University Medical Center, Chicago, IL (P.G.R.); UCSF Cancer Registry, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (A.G.); Helen Diller Family Comprehensive Cancer Center, University of California San Francisco (D.I.A., J.H., L.D.K., J.A.L., P.V., P.A.T., J.L.R.); Biostatistics and Computational Biology Core, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (J.H.); Center for AIDS Research; UCSF Gladstone Institute of Virology and Immunology (P.V.)
| |
Collapse
|
381
|
Debliquis A, Voirin J, Harzallah I, Maurer M, Lerintiu F, Drénou B, Ahle G. Cytomorphology and flow cytometry of brain biopsy rinse fluid enables faster and multidisciplinary diagnosis of large B-cell lymphoma of the central nervous system. CYTOMETRY PART B-CLINICAL CYTOMETRY 2016; 94:182-188. [DOI: 10.1002/cyto.b.21403] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/21/2016] [Revised: 07/04/2016] [Accepted: 07/29/2016] [Indexed: 11/12/2022]
Affiliation(s)
- Agathe Debliquis
- Groupe Hospitalier de la Région Mulhouse Sud Alsace; Laboratoire d'Hématologie; France
| | - Jimmy Voirin
- Service de Neurochirurgie, Hôpitaux Civils de Colmar et Hautepierre; Strasbourg France
| | - Inès Harzallah
- Groupe Hospitalier de la Région Mulhouse Sud Alsace; Laboratoire d'Hématologie; France
| | - Maxime Maurer
- Laboratoire d'Hématologie, Hôpitaux Civils de Colmar; France
| | - Felix Lerintiu
- Service d'Anatomo-Pathologie, Hôpitaux Civils de Colmar; France
| | - Bernard Drénou
- Groupe Hospitalier de la Région Mulhouse Sud Alsace; Laboratoire d'Hématologie; France
| | - Guido Ahle
- Service de Neurologie, Hôpitaux Civils de Colmar; France
| |
Collapse
|
382
|
Doorduijn JK, van Imhoff GW, van der Holt B, Schouten HC, Schaafsma MR, MacKenzie MA, Baars JW, Kersten MJ, Lugtenburg PJ, van den Bent MJ, Enting RH, Spoelstra FM, Poortmans P, Bromberg JEC. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study. Hematol Oncol 2016; 35:497-503. [PMID: 27530779 DOI: 10.1002/hon.2342] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2015] [Revised: 06/06/2016] [Accepted: 07/13/2016] [Indexed: 12/21/2022]
Abstract
The prognosis of central nervous system (CNS) relapse of systemic non-Hodgkin lymphoma is poor with 1-year survival historically at 0% to 20%. Aiming to improve these results, we performed a multicenter phase 2 study in patients with a CNS relapse, with or without concurrent systemic relapse. Treatment consisted of 2 cycles of R-DHAP alternating with high-dose methotrexate (MTX) and was combined with intrathecal rituximab. Responding patients received a third R-DHAP-MTX cycle followed by busulfan and cyclophosphamide myeloablative therapy and autologous stem cell transplantation. In patients with persistent cerebrospinal fluid lymphoma after cycle 1, the intrathecal rituximab was replaced by intrathecal triple therapy, with MTX, cytarabine, and dexamethasone. Thirty-six patients were included. Eighteen had evidence of cerebrospinal fluid lymphoma, 24 had brain parenchymal disease, and 20 (56%) had concurrent systemic disease. The overall response rate after 2 R-DHAP-MTX was 53% (19/36), with 22% (8/36) complete remission. Fifteen patients (42%) underwent a transplant. One-year progression-free survival was 19% (95% confidence interval, 9-34): 25% in patients without and 15% in patients with systemic disease. One-year overall survival was 25% (95% confidence interval, 12-40). This treatment regimen did not result in a major improvement of outcome of secondary CNS lymphoma, especially when concurrent systemic disease was present. Registered in the Dutch trial register www.trialregister.nl, NTR1757; EudraCT number 2006-002141-37.
Collapse
Affiliation(s)
- Jeanette K Doorduijn
- Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| | - Gustaaf W van Imhoff
- Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands
| | - Bronno van der Holt
- HOVON Data Center, Erasmus MC Cancer Institute-Clinical Trial Center, Rotterdam, The Netherlands
| | - Harry C Schouten
- Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands
| | - Martijn R Schaafsma
- Department of Internal Medicine, Medisch Spectrum Twente, Enschede, The Netherlands
| | - Marius A MacKenzie
- Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Joke W Baars
- Department of Medical Oncology, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - Marie José Kersten
- Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands
| | | | - Martin J van den Bent
- Department of Neuro-oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| | - Roelien H Enting
- Department of Neurology, University Medical Center Groningen, Groningen, The Netherlands
| | - Fokje M Spoelstra
- HOVON Data Center, Erasmus MC Cancer Institute-Clinical Trial Center, Rotterdam, The Netherlands
| | - Philip Poortmans
- Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Jacoline E C Bromberg
- Department of Neuro-oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| |
Collapse
|
383
|
Chihara D, Fowler NH, Oki Y, Fanale MA, Fayad LE, Westin JR, Hagemeister FB. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement. Br J Haematol 2016; 179:851-854. [PMID: 27502933 DOI: 10.1111/bjh.14267] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
- Dai Chihara
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Nathan H Fowler
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Yasuhiro Oki
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Michelle A Fanale
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Luis E Fayad
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jason R Westin
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Fredrick B Hagemeister
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|
384
|
Illerhaus G, Kasenda B, Ihorst G, Egerer G, Lamprecht M, Keller U, Wolf HH, Hirt C, Stilgenbauer S, Binder M, Hau P, Edinger M, Frickhofen N, Bentz M, Möhle R, Röth A, Pfreundschuh M, von Baumgarten L, Deckert M, Hader C, Fricker H, Valk E, Schorb E, Fritsch K, Finke J. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. LANCET HAEMATOLOGY 2016; 3:e388-97. [PMID: 27476790 DOI: 10.1016/s2352-3026(16)30050-3] [Citation(s) in RCA: 111] [Impact Index Per Article: 13.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/01/2016] [Revised: 05/19/2016] [Accepted: 05/20/2016] [Indexed: 10/21/2022]
Abstract
BACKGROUND High-dose methotrexate-based chemotherapy is standard for primary CNS lymphoma, but most patients relapse. High-dose chemotherapy with autologous stem cell transplantation (HCT-ASCT) is supposed to overcome the blood-brain barrier and eliminate residual disease in the CNS. We aimed to investigate the safety and efficacy of HCT-ASCT in patients with newly diagnosed primary CNS lymphoma. METHODS In this prospective, single-arm, phase 2 trial, we recruited patients aged 18-65 years with newly diagnosed primary CNS lymphoma and immunocompetence, with no limitation on clinical performance status, from 15 hospitals in Germany. Patients received five courses of intravenous rituximab 375 mg/m(2) (7 days before first high-dose methotrexate course and then every 10 days) and four courses of intravenous high-dose methotrexate 8000 mg/m(2) (every 10 days) and then two courses of intravenous rituximab 375 mg/m(2) (day 1), cytarabine 3 g/m(2) (days 2 and 3), and thiotepa 40 mg/m(2) (day 3). 3 weeks after the last course, patients commenced intravenous HCT-ASCT (rituximab 375 mg/m(2) [day 1], carmustine 400 mg/m(2) [day 2], thiotepa 2 × 5 mg/kg [days 3 and 4], and infusion of stem cells [day 7]), irrespective of response status after induction. We restricted radiotherapy to patients without complete response after HCT-ASCT. The primary endpoint was complete response at day 30 after HCT-ASCT in all registered eligible patients who received at least 1 day of study treatment. This trial is registered at ClinicalTrials.gov, number NCT00647049. FINDINGS Between Jan 18, 2007, and May 23, 2011, we recruited 81 patients, of whom two (2%) were excluded, therefore we included 79 (98%) patients in the analysis. All patients started induction treatment; 73 (92%) commenced HCT-ASCT. 61 (77·2% [95% CI 66·1-86·6]) patients achieved a complete response. During induction treatment, the most common grade 3 toxicity was anaemia (37 [47%]) and the most common grade 4 toxicity was thrombocytopenia (50 [63%]). During HCT-ASCT, the most common grade 3 toxicity was fever (50 [68%] of 73) and the most common grade 4 toxicity was leucopenia (68 [93%] of 73). We recorded four (5%) treatment-related deaths (three [4%] during induction and one [1%] 4 weeks after HCT-ASCT). INTERPRETATION HCT-ASCT with thiotepa and carmustine is an effective treatment option in young patients with newly diagnosed primary CNS lymphoma, but further comparative studies are needed. FUNDING University Hospital Freiburg and Amgen.
Collapse
Affiliation(s)
- Gerald Illerhaus
- Department of Haematology/Oncology and Palliative Care, Klinikum Stuttgart, Stuttgart, Germany; Department of Hematology, Oncology, and Stem-Cell Transplantation, University Medical Hospital and Faculty of Medicine, Albert-Ludwigs University, Freiburg, Germany.
| | - Benjamin Kasenda
- Department of Haematology/Oncology and Palliative Care, Klinikum Stuttgart, Stuttgart, Germany; Department of Medicine, Royal Marsden Hospital, London, UK
| | - Gabriele Ihorst
- Clinical Trials Unit, University of Freiburg Medical Centre, Freiburg, Germany
| | - Gerlinde Egerer
- Department of Haematology and Oncology, Heidelberg University, Heidelberg, Germany
| | - Monika Lamprecht
- Department of Internal Medicine II, University Hospital of Schleswig-Holstein, Kiel, Germany
| | - Ulrich Keller
- III Medical Department, Technische Universität München, Munich, Germany
| | - Hans-Heinrich Wolf
- Department of Haematology and Oncology, University Hospital Halle, Halle, Germany
| | - Carsten Hirt
- Hematology and Oncology, Clinic for Internal Medicine C, University of Greifswald, Greifswald, Germany
| | | | - Mascha Binder
- Department of Internal Medicine II, Oncology, Hematology, and Bone Marrow Transplantation with section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Peter Hau
- Department of Neurology and Wilhelm Sander-NeuroOncology Unit, University Hospital Regensburg, Regensburg, Germany
| | - Matthias Edinger
- Department of Medicine, University Hospital Regensburg, Regensburg, Germany
| | - Norbert Frickhofen
- Department of Haematology and Oncology, HELIOS Dr Horst Schmidt Kliniken, Wiesbaden, Germany
| | - Martin Bentz
- Medizinische Klinik, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany
| | - Robert Möhle
- Department of Haematology and Oncology, University of Tübingen, Tübingen, Germany
| | - Alexander Röth
- Department of Haematology, Medical Faculty, University of Duisburg-Essen, Essen, Germany
| | | | | | - Martina Deckert
- Institute of Neuropathology, University Hospital of Cologne, Cologne, Germany
| | - Claudia Hader
- Department of Neuroradiology, University Hospital Freiburg, Freiburg, Germany
| | - Heidi Fricker
- Department of Hematology, Oncology, and Stem-Cell Transplantation, University Medical Hospital and Faculty of Medicine, Albert-Ludwigs University, Freiburg, Germany
| | - Elke Valk
- Department of Haematology/Oncology and Palliative Care, Klinikum Stuttgart, Stuttgart, Germany
| | - Elisabeth Schorb
- Department of Hematology, Oncology, and Stem-Cell Transplantation, University Medical Hospital and Faculty of Medicine, Albert-Ludwigs University, Freiburg, Germany
| | - Kristina Fritsch
- Department of Hematology, Oncology, and Stem-Cell Transplantation, University Medical Hospital and Faculty of Medicine, Albert-Ludwigs University, Freiburg, Germany
| | - Jürgen Finke
- Department of Hematology, Oncology, and Stem-Cell Transplantation, University Medical Hospital and Faculty of Medicine, Albert-Ludwigs University, Freiburg, Germany
| |
Collapse
|
385
|
Huang WY, Wen JB, Wu G, Yin B, Li JJ, Geng DY. Diffusion-Weighted Imaging for Predicting and Monitoring Primary Central Nervous System Lymphoma Treatment Response. AJNR Am J Neuroradiol 2016; 37:2010-2018. [PMID: 27390318 DOI: 10.3174/ajnr.a4867] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2016] [Accepted: 05/11/2016] [Indexed: 12/13/2022]
Abstract
BACKGROUND AND PURPOSE Whether ADC value predicts the therapy response and outcomes of primary central system lymphoma remains controversial. This study assessed the minimum ADC correlated with treatment response in patients with primary central nervous system lymphoma undergoing methotrexate-based chemotherapy. MATERIALS AND METHODS Thirty-five patients with primary central nervous system lymphoma underwent conventional MR imaging and DWI before chemotherapy and after 1 and 5 cycles of chemotherapy. Treatment response was determined according to the International PCNSL Collaborative Group criteria and was classified as a complete response, partial response, or progressive disease. Pretreatment minimum ADC, minimum ADC after 1 cycle, minimum ADC after 5 cycles, and change in minimum ADC were compared among the different response groups. The Pearson correlation test was calculated between these ADC parameters and tumor response. RESULTS The pretreatment minimum ADC of the progressive disease group was lower than that of the complete response and partial response groups, but there was no significant difference among them. The minimum ADC after 1 cycle and minimum ADC after 5 cycles were statistically significantly higher than the pretreatment minimum ADC. A comparison among groups showed that minimum ADC after 1 cycle, minimum ADC after 5 cycles, minimum ADC change, and the percentage of minimum ADC change were all significantly different among the 3 groups. A significant positive correlation was observed between the percentage of minimum ADC after 1 cycle of chemotherapy and the size reduction percentage after 5 cycles of chemotherapy. The minimum ADC change and the percentage of minimum ADC change performed better in the differentiation of the final treatment response, specifically in complete response and partial response from progressive disease. CONCLUSIONS The minimum ADC after 1 cycle and minimum ADC changes were better correlated with the treatment response than the pretreatment minimum ADC. Minimum ADC after early therapy may potentially to be used to predict and monitor the response of primary central nervous system lymphoma to chemotherapy.
Collapse
Affiliation(s)
- W-Y Huang
- From the Departments of Radiology (W.-Y.H., J.-J.L.)
| | - J-B Wen
- Department of Radiology (J.-B.W., B.Y., D.-Y.G.), Huashan Hospital, Fudan University, Shanghai, China
| | - G Wu
- Radiotherapy (G.W.), Hainan General Hospital, Haikou, Hainan, China
| | - B Yin
- Department of Radiology (J.-B.W., B.Y., D.-Y.G.), Huashan Hospital, Fudan University, Shanghai, China
| | - J-J Li
- From the Departments of Radiology (W.-Y.H., J.-J.L.)
| | - D-Y Geng
- Department of Radiology (J.-B.W., B.Y., D.-Y.G.), Huashan Hospital, Fudan University, Shanghai, China.
| |
Collapse
|
386
|
Nguyen-Them L, Costopoulos M, Tanguy ML, Houillier C, Choquet S, Benanni H, Elias-Shamieh R, Armand M, Faivre G, Glaisner S, Malak S, Vargaftig J, Hoang-Xuan K, Ahle G, Touitou V, Cassoux N, Davi F, Merle-Béral H, Le Garff-Tavernier M, Soussain C. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients. Eur J Cancer 2016; 61:69-76. [DOI: 10.1016/j.ejca.2016.03.080] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2016] [Revised: 03/17/2016] [Accepted: 03/26/2016] [Indexed: 10/21/2022]
|
387
|
Valls L, Badve C, Avril S, Herrmann K, Faulhaber P, O'Donnell J, Avril N. FDG-PET imaging in hematological malignancies. Blood Rev 2016; 30:317-31. [PMID: 27090170 PMCID: PMC5298348 DOI: 10.1016/j.blre.2016.02.003] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2015] [Revised: 02/12/2016] [Accepted: 02/19/2016] [Indexed: 12/12/2022]
Abstract
The majority of aggressive lymphomas is characterized by an up regulated glycolytic activity, which enables the visualization by F-18 FDG-PET/CT. One-stop hybrid FDG-PET/CT combines the functional and morphologic information, outperforming both, CT and FDG-PET as separate imaging modalities. This has resulted in several recommendations using FDG-PET/CT for staging, restaging, monitoring during therapy, and assessment of treatment response as well as identification of malignant transformation. FDG-PET/CT may obviate the need for a bone marrow biopsy in patients with Hodgkin's lymphoma and diffuse large B cell lymphoma. FDG-PET/CT response assessment is recommended for FDG-avid lymphomas, whereas CT-based response evaluation remains important in lymphomas with low or variable FDG avidity. The treatment induced change in metabolic activity allows for assessment of response after completion of therapy as well as prediction of outcome early during therapy. The five-point scale Deauville Criteria allows the assessment of treatment response based on visual FDG-PET analysis. Although the use of FDG-PET/CT for prediction of therapeutic response is promising it should only be conducted in the context of clinical trials. Surveillance FDG-PET/CT after complete remission is discouraged due to the relative high number of false-positive findings, which in turn may result in further unnecessary investigations. Future directions include the use of new PET tracers such as F-18 fluorothymidine (FLT), a surrogate biomarker of cellular proliferation and Ga-68 CXCR4, a chemokine receptor imaging biomarker as well as innovative digital PET/CT and PET/MRI techniques.
Collapse
Affiliation(s)
- L Valls
- Department of Radiology, University Hospitals Case Medical Center, Case Center for Imaging Research, Case Western Reserve University, Cleveland, OH 44106, USA
| | - C Badve
- Department of Radiology, University Hospitals Case Medical Center, Case Center for Imaging Research, Case Western Reserve University, Cleveland, OH 44106, USA
| | - S Avril
- Department of Pathology, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH 44106, USA
| | - K Herrmann
- Department of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, Germany; Ahmanson Translational Imaging Division, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-7370, USA
| | - P Faulhaber
- Department of Radiology, University Hospitals Case Medical Center, Case Center for Imaging Research, Case Western Reserve University, Cleveland, OH 44106, USA
| | - J O'Donnell
- Department of Radiology, University Hospitals Case Medical Center, Case Center for Imaging Research, Case Western Reserve University, Cleveland, OH 44106, USA
| | - N Avril
- Department of Radiology, University Hospitals Case Medical Center, Case Center for Imaging Research, Case Western Reserve University, Cleveland, OH 44106, USA.
| |
Collapse
|
388
|
The role of whole brain radiation in primary CNS lymphoma. Blood 2016; 128:32-6. [PMID: 27207798 DOI: 10.1182/blood-2016-01-650101] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2016] [Accepted: 05/03/2016] [Indexed: 12/19/2022] Open
|
389
|
Scharf EL, Hanson CA, Howard MT, Keegan BM. Serial cerebrospinal fluid examinations to diagnose hematological malignancy causing neurological disease. J Neurooncol 2016; 129:77-83. [DOI: 10.1007/s11060-016-2140-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2016] [Accepted: 05/03/2016] [Indexed: 10/21/2022]
|
390
|
Ferreri AJM, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 2016; 3:e217-27. [PMID: 27132696 DOI: 10.1016/s2352-3026(16)00036-3] [Citation(s) in RCA: 376] [Impact Index Per Article: 47.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2016] [Revised: 02/24/2016] [Accepted: 03/03/2016] [Indexed: 12/16/2022]
Abstract
BACKGROUND Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk of haematological or neurological toxicity. In this trial, we addressed the tolerability and efficacy of adding rituximab with or without thiotepa to methotrexate-cytarabine combination therapy (the MATRix regimen), followed by a second randomisation comparing consolidation with whole-brain radiotherapy or autologous stem cell transplantation in patients with primary CNS lymphoma. We report the results of the first randomisation in this Article. METHODS For the international randomised phase 2 International Extranodal Lymphoma Study Group-32 (IELSG32) trial, HIV-negative patients (aged 18-70 years) with newly diagnosed primary CNS lymphoma and measurable disease were enrolled from 53 cancer centres in five European countries (Denmark, Germany, Italy, Switzerland, and the UK) and randomly assigned (1:1:1) to receive four courses of methotrexate 3·5 g/m(2) on day 1 plus cytarabine 2 g/m(2) twice daily on days 2 and 3 (group A); or the same combination plus two doses of rituximab 375 mg/m(2) on days -5 and 0 (group B); or the same methotrexate-cytarabine-rituximab combination plus thiotepa 30 mg/m(2) on day 4 (group C), with the three groups repeating treatment every 3 weeks. Patients with responsive or stable disease after the first stage were then randomly allocated between whole-brain radiotherapy and autologous stem cell transplantation. A permuted blocks randomised design (block size four) was used for both randomisations, and a computer-generated randomisation list was used within each stratum to preserve allocation concealment. Randomisation was stratified by IELSG risk score (low vs intermediate vs high). No masking after assignment to intervention was used. The primary endpoint of the first randomisation was the complete remission rate, analysed by modified intention to treat. This study is registered with ClinicalTrials.gov, number NCT01011920. FINDINGS Between Feb 19, 2010, and Aug 27, 2014, 227 eligible patients were recruited. 219 of these 227 enrolled patients were assessable. At median follow-up of 30 months (IQR 22-38), patients treated with rituximab and thiotepa had a complete remission rate of 49% (95% CI 38-60), compared with 23% (14-31) of those treated with methotrexate-cytarabine alone (hazard ratio 0·46, 95% CI 0·28-0·74) and 30% (21-42) of those treated with methotrexate-cytarabine plus rituximab (0·61, 0·40-0·94). Grade 4 haematological toxicity was more frequent in patients treated with methotrexate-cytarabine plus rituximab and thiotepa, but infective complications were similar in the three groups. The most common grade 3-4 adverse events in all three groups were neutropenia, thrombocytopenia, anaemia, and febrile neutropenia or infections. 13 (6%) patients died of toxicity. INTERPRETATION With the limitations of a randomised phase 2 study design, the IELSG32 trial provides a high level of evidence supporting the use of MATRix combination as the new standard chemoimmunotherapy for patients aged up to 70 years with newly diagnosed primary CNS lymphoma and as the control group for future randomised trials. FUNDING Associazione Italiana del Farmaco, Cancer Research UK, Oncosuisse, and Swiss National Foundation.
Collapse
Affiliation(s)
- Andrés J M Ferreri
- Unit of Lymphoid Malignancies, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
| | - Kate Cwynarski
- Royal Free Hospital/University College London Hospital, London, UK
| | | | - Maurilio Ponzoni
- Ateneo Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy; Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Martina Deckert
- Institute of Neuropathology, University Hospital of Cologne, Cologne, Germany
| | - Letterio S Politi
- Unit of Neuroradiology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Valter Torri
- IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| | | | | | | | - Achille Ambrosetti
- Dipartimento di Medicina, Sezione di Ematologia, Università di Verona, Verona, Italy
| | | | | | - Angela Ferrari
- Azienda Ospedaliera Arcispedale Santa Maria Nuova IRCCS, Reggio Emilia, Italy
| | - Kim M Linton
- The Christie Hospital NHS Foundation Trust, Manchester, UK
| | - Roberta Rudà
- AOU Città Della Salute e Della Scienza di Torino, Turin, Italy
| | - Mascha Binder
- Uke Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
| | | | | | | | - Peter Johnson
- Medical Oncology Unit, Southampton General Hospital, Southampton, UK
| | | | | | - Jens Panse
- Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital Aachen, Medical Faculty, RWTH Aachen University, Aachen, Germany
| | - Francesco Pisani
- Hematology and Stem Cell Transplantation Unit, Istituto Nazionale dei Tumori Regina Elena, Rome, Italy
| | | | | | | | | | | | | | | | - Franco Cavalli
- Istituto Oncologico Della Svizzera Italiana, Bellinzona, Switzerland
| | | | - Michele Reni
- Department of Medical Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Emanuele Zucca
- Istituto Oncologico Della Svizzera Italiana, Bellinzona, Switzerland
| | | |
Collapse
|
391
|
Schorb E, Finke J, Ferreri AJM, Ihorst G, Mikesch K, Kasenda B, Fritsch K, Fricker H, Burger E, Grishina O, Valk E, Zucca E, Illerhaus G. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix). BMC Cancer 2016; 16:282. [PMID: 27098429 PMCID: PMC4839072 DOI: 10.1186/s12885-016-2311-4] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2015] [Accepted: 04/12/2016] [Indexed: 02/08/2023] Open
Abstract
Background Primary central nervous system lymphoma (PCNSL) is a highly aggressive Non-Hodgkin lymphoma (NHL) with rising incidence over the past 30 years in immunocompetent patients. Although outcomes have improved, PCNSL is still associated with inferior prognosis compared to systemic NHL. Many questions regarding the optimal therapeutic approach remain unanswered. Methods/Design This is a randomized, open-label, international phase III trial with two parallel arms. We will recruit 250 patients with newly diagnosed PCNSL from approximately 35 centers within the networks of the German Cooperative PCNSL study group and the International Extranodal Lymphoma Study Group. All enrolled patients will undergo induction chemotherapy consisting of 4 cycles of rituximab 375 mg/m2/d (days 0 & 5), methotrexate 3.5 g/m2 (d1), cytarabine 2 × 2 g/m2/d (d2-3), and thiotepa 30 mg/m2 (d4) every 21 days. All patients will undergo stem-cell harvest after the second cycle. After 4 cycles of induction chemotherapy, patients achieving partial or complete response will be centrally randomized to 2 different consolidation treatments: (A) conventional-dose immuno chemotherapy with rituximab 375 mg/m2 (d0), dexamethasone 40 mg/d (d1-3), etoposide 100 mg/m2/d (d1-3), ifosfamide 1500 mg/m2/d (d1-3) and carboplatin 300 mg/m2 (d1) (R-DeVIC) or (B) high-dose chemotherapy with BCNU (or busulfan) and thiotepa followed by autologous stem cell transplantation (HCT-ASCT). The objective is to demonstrate superiority of HCT-ASCT compared to R-DeVIC with respect to progression-free survival (PFS, primary endpoint). Secondary endpoints include overall survival (OS), treatment response and treatment-related morbidities. Minimal follow-up after treatment completion is 24 months. Discussion The rationale for consolidation treatment in PCNSL is to eliminate residual lymphoma cells and to decrease the risk for relapse. This can be achieved by agents crossing the blood brain barrier either applied at conventional doses or at high doses requiring autologous stem cell support. HCT-ASCT has been shown to be feasible and highly effective in patients with newly-diagnosed PCNSL. However, it is unclear whether HCT-ASCT is really superior compared to conventional-dose chemotherapy after an intensified antimetabolites-based immunochemotherapy in patients with newly-diagnosed PCNSL. To answer this question, we designed this investigator initiated randomized phase III trial. Trial registration German clinical trials registry DRKS00005503 registered 22 April 2014 and ClinicalTrials.gov NCT02531841 registered 24 August 2015. Electronic supplementary material The online version of this article (doi:10.1186/s12885-016-2311-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Elisabeth Schorb
- Department of Hematology/Oncology, Freiburg University Medical Center, Freiburg, Germany
| | - Juergen Finke
- Department of Hematology/Oncology, Freiburg University Medical Center, Freiburg, Germany
| | - Andrés J M Ferreri
- Unit of Lymphoid Malignancies, Head Division of OncoHematological Medicine, Department of OncoHematology, San Raffaele Scientific Institute, Milan, Italy
| | - Gabriele Ihorst
- Clinical Trials Unit, Freiburg University Medical Center, Freiburg, Germany
| | - Kristina Mikesch
- Clinic of Hematology, Oncology and Palliative Care, Klinikum Stuttgart, Kriegsbergstr.60, Stuttgart, 70174, Germany
| | - Benjamin Kasenda
- Clinic of Hematology, Oncology and Palliative Care, Klinikum Stuttgart, Kriegsbergstr.60, Stuttgart, 70174, Germany
| | - Kristina Fritsch
- Department of Hematology/Oncology, Freiburg University Medical Center, Freiburg, Germany
| | - Heidi Fricker
- Department of Hematology/Oncology, Freiburg University Medical Center, Freiburg, Germany
| | - Elvira Burger
- Clinical Trials Unit, Freiburg University Medical Center, Freiburg, Germany
| | - Olga Grishina
- Clinical Trials Unit, Freiburg University Medical Center, Freiburg, Germany
| | - Elke Valk
- Clinic of Hematology, Oncology and Palliative Care, Klinikum Stuttgart, Kriegsbergstr.60, Stuttgart, 70174, Germany
| | - Emanuele Zucca
- Oncology Institute of Southern Switzerland, San Giovanni Hospital, Bellinzona, Switzerland
| | - Gerald Illerhaus
- Clinic of Hematology, Oncology and Palliative Care, Klinikum Stuttgart, Kriegsbergstr.60, Stuttgart, 70174, Germany.
| |
Collapse
|
392
|
Mocikova H, Pytlik R, Sykorova A, Janikova A, Prochazka V, Vokurka S, Berkova A, Belada D, Campr V, Buresova L, Trneny M. Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry. Leuk Lymphoma 2016; 57:2777-2783. [PMID: 27087066 DOI: 10.3109/10428194.2016.1167203] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
We have investigated whether the addition of rituximab to methotrexate, procarbazine, vincristine, radiotherapy and cytarabine was associated with improved outcome of primary central nervous system lymphomas (PCNSL). Of 164 patients, 49 received rituximab. Median age was 63 years, median Karnofsky performance score (KPS) was 60 and median follow-up of living patients was 59.5 months. 1- and 2-year PFS were 49.7 and 37.9%, 1- and 2-year OS were 57.0 and 45.3%. Median progression-free survival (PFS), but not overall survival (OS) was significantly better for patients treated with rituximab (22.9 vs. 10.9 months, p = 0.037). In multivariate analysis, age ≤70 years and KPS ≥90 were predictive for PFS and OS, rituximab was an independent prognostic factor for PFS only. In landmark analyses, rituximab was not found beneficial for long-term survivors and no group particularly benefited from rituximab. In conclusion, addition of rituximab was associated with improved PFS, but not OS in this unselected cohort of PCNSL patients.
Collapse
Affiliation(s)
- Heidi Mocikova
- a Department for Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine , Charles University in Prague , Czech Republic
| | - Robert Pytlik
- b First Medical Department - Clinical Department of Haemato-oncology , First Faculty of Medicine and General Teaching Hospital, Charles University in Prague , Czech Republic
| | - Alice Sykorova
- c Fourth Department of Internal Medicine - Hematology , Charles University Hospital and Faculty of Medicine , Hradec Kralove , Czech Republic
| | - Andrea Janikova
- d Department of Internal Medicine and Hemato-oncology , University Hospital , Brno , Czech Republic
| | - Vit Prochazka
- e Department of Hemato-oncology, Faculty of Medicine and Dentistry , Palacky University and University Hospital Olomouc , Czech Republic
| | - Samuel Vokurka
- f Department of Hemato-oncology , University Hospital , Pilsen , Czech Republic
| | - Adela Berkova
- b First Medical Department - Clinical Department of Haemato-oncology , First Faculty of Medicine and General Teaching Hospital, Charles University in Prague , Czech Republic
| | - David Belada
- c Fourth Department of Internal Medicine - Hematology , Charles University Hospital and Faculty of Medicine , Hradec Kralove , Czech Republic
| | - Vit Campr
- g Institute of Pathology and Molecular Medicine, Second Faculty of Medicine , Charles University in Prague , Czech Republic
| | | | - Marek Trneny
- b First Medical Department - Clinical Department of Haemato-oncology , First Faculty of Medicine and General Teaching Hospital, Charles University in Prague , Czech Republic
| | | |
Collapse
|
393
|
Igala M. Unusual relapse of primary central nervous system lymphoma. SPRINGERPLUS 2016; 5:301. [PMID: 27066337 PMCID: PMC4783311 DOI: 10.1186/s40064-016-1926-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/02/2015] [Accepted: 02/23/2016] [Indexed: 11/10/2022]
Abstract
Primary central nervous system lymphoma (PCNSL) is a rare disease which accounts for 1-2 % of non-Hodgkin lymphoma and 3-5 % of primary brain tumor lesions. PCNSL of an immunocompetent patient is an uncommon disease, it is estimated at 4 % of new diagnoses of CNS tumors. The prognosis of PCNSL is poor compared to other extranodal lymphomas, with a 5-year survival estimated between 20 and 40 %. PCNSL relapse occurs either in the original site but still confined to the CNS or exceptionally outside it. Brain magnetic resonance imaging, although not allowing a clear distinction between primary lesions and secondary brain lymphoma is of paramount importance not only for diagnosis but also for monitoring the patient. This manuscript report the case of a patient in whom the PCNSL has relapsed in the cervical spinal cord and also in the liver.
Collapse
Affiliation(s)
- Marielle Igala
- Hematology Department, Hôpital du 20 Aôut, Centre hospitalier universitaire de Casablanca, Casablanca, Morocco
| |
Collapse
|
394
|
Jang JE, Kim YR, Kim SJ, Cho H, Chung H, Lee JY, Park H, Kim Y, Cheong JW, Min YH, Kim JS. A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma. Eur J Cancer 2016; 57:127-35. [DOI: 10.1016/j.ejca.2016.01.016] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2015] [Revised: 01/10/2016] [Accepted: 01/20/2016] [Indexed: 01/09/2023]
|
395
|
Cho H, Chang JH, Kim YR, Kim SJ, Chung H, Park H, Lee JY, Jang JE, Kim Y, Kim SH, Yang WI, Suh CO, Cheong JW, Min YH, Kim JS. The role of upfront autologous stem cell transplantation in high-risk younger patients with primary central nervous system lymphoma. Br J Haematol 2016; 174:444-53. [DOI: 10.1111/bjh.14069] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2015] [Accepted: 01/26/2016] [Indexed: 11/27/2022]
Affiliation(s)
- Hyunsoo Cho
- Division of Haematology; Department of Internal Medicine; Severance Hospital; Yonsei University College of Medicine; Seoul South Korea
| | - Jong Hee Chang
- Department of Neurosurgery; Severance Hospital; Yonsei University College of Medicine; Seoul South Korea
| | - Yu Ri Kim
- Department of Internal Medicine; Gangnam Severance Hospital; Yonsei University College of Medicine; Seoul South Korea
| | - Soo-Jeong Kim
- Division of Haematology; Department of Internal Medicine; Severance Hospital; Yonsei University College of Medicine; Seoul South Korea
| | - Haerim Chung
- Division of Haematology; Department of Internal Medicine; Severance Hospital; Yonsei University College of Medicine; Seoul South Korea
| | - Hyunsung Park
- Division of Haematology; Department of Internal Medicine; Severance Hospital; Yonsei University College of Medicine; Seoul South Korea
| | - Jung Yeon Lee
- Division of Haematology; Department of Internal Medicine; Severance Hospital; Yonsei University College of Medicine; Seoul South Korea
| | - Ji Eun Jang
- Division of Haematology; Department of Internal Medicine; Severance Hospital; Yonsei University College of Medicine; Seoul South Korea
| | - Yundeok Kim
- Division of Haematology; Department of Internal Medicine; Severance Hospital; Yonsei University College of Medicine; Seoul South Korea
| | - Se Hoon Kim
- Department of Pathology; Severance Hospital; Yonsei University College of Medicine; Seoul South Korea
| | - Woo Ick Yang
- Department of Pathology; Severance Hospital; Yonsei University College of Medicine; Seoul South Korea
| | - Chang-Ok Suh
- Department of Radiation Oncology; Severance Hospital; Yonsei University College of Medicine; Seoul South Korea
| | - June-Won Cheong
- Division of Haematology; Department of Internal Medicine; Severance Hospital; Yonsei University College of Medicine; Seoul South Korea
| | - Yoo Hong Min
- Division of Haematology; Department of Internal Medicine; Severance Hospital; Yonsei University College of Medicine; Seoul South Korea
| | - Jin Seok Kim
- Division of Haematology; Department of Internal Medicine; Severance Hospital; Yonsei University College of Medicine; Seoul South Korea
| |
Collapse
|
396
|
Korfel A, Schlegel U, Herrlinger U, Dreyling M, Schmidt C, von Baumgarten L, Pezzutto A, Grobosch T, Kebir S, Thiel E, Martus P, Kiewe P. Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma. J Clin Oncol 2016; 34:1757-63. [PMID: 26976424 DOI: 10.1200/jco.2015.64.9897] [Citation(s) in RCA: 87] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
PURPOSE In this phase II study (NCT00942747), temsirolimus was tested in patients with relapsed or refractory primary CNS lymphoma (PCNSL). PATIENTS AND METHODS Immunocompetent adults with histologically confirmed PCNSL after experiencing high-dose methotrexate-based chemotherapy failure who were not eligible for or had experienced high-dose chemotherapy with autologous stem-cell transplant failure were included. The first cohort (n = 6) received 25 mg temsirolimus intravenously once per week. All consecutive patients received 75 mg intravenously once per week. RESULTS Thirty-seven eligible patients (median age, 70 years) were included whose median time since their last treatment was 3.9 months (range, 0.1 to 14.6 months). Complete response was seen in five patients (13.5%), complete response unconfirmed in three (8%), and partial response in 12 (32.4%) for an overall response rate of 54%. Median progression-free survival was 2.1 months (95% CI, 1.1 to 3.0 months). The most frequent Common Toxicity Criteria ≥ 3° adverse event was hyperglycemia in 11 (29.7%) patients, thrombocytopenia in eight (21.6%), infection in seven (19%), anemia in four (10.8%), and rash in three (8.1%). Fourteen blood/CSF pairs were collected in nine patients (10 pairs in five patients in the 25-mg cohort and four pairs in four patients in the 75-mg cohort). The mean maximum blood concentration was 292 ng/mL for temsirolimus and 37.2 ng/mL for its metabolite sirolimus in the 25-mg cohort and 484 ng/mL and 91.1 ng/mL, respectively, in the 75-mg cohort. Temsirolimus CSF concentration was 2 ng/mL in one patient in the 75-mg cohort; in all others, no drug was found in their CSF. CONCLUSION Single-agent temsirolimus at a weekly dose of 75 mg was found to be active in relapsed/refractory patients with PCNSL; however, responses were usually short lived.
Collapse
Affiliation(s)
- Agnieszka Korfel
- Agnieszka Korfel, Antonio Pezzutto, Eckhard Thiel, and Philipp Kiewe, Charité University Medicine Berlin; Thomas Grobosch, Labor Berlin - Charité Vivantes, Berlin; Uwe Schlegel, Ruhr-Universität Bochum, Bochum; Ulrich Herrlinger and Sied Kebir, University Hospital Bonn, Bonn; Martin Dreyling, Christian Schmidt, and Luisa von Baumgarten, Hospital of the Ludwig Maximilian University München, Munich; and Peter Martus, University Tuebingen, Tuebingen, Germany.
| | - Uwe Schlegel
- Agnieszka Korfel, Antonio Pezzutto, Eckhard Thiel, and Philipp Kiewe, Charité University Medicine Berlin; Thomas Grobosch, Labor Berlin - Charité Vivantes, Berlin; Uwe Schlegel, Ruhr-Universität Bochum, Bochum; Ulrich Herrlinger and Sied Kebir, University Hospital Bonn, Bonn; Martin Dreyling, Christian Schmidt, and Luisa von Baumgarten, Hospital of the Ludwig Maximilian University München, Munich; and Peter Martus, University Tuebingen, Tuebingen, Germany
| | - Ulrich Herrlinger
- Agnieszka Korfel, Antonio Pezzutto, Eckhard Thiel, and Philipp Kiewe, Charité University Medicine Berlin; Thomas Grobosch, Labor Berlin - Charité Vivantes, Berlin; Uwe Schlegel, Ruhr-Universität Bochum, Bochum; Ulrich Herrlinger and Sied Kebir, University Hospital Bonn, Bonn; Martin Dreyling, Christian Schmidt, and Luisa von Baumgarten, Hospital of the Ludwig Maximilian University München, Munich; and Peter Martus, University Tuebingen, Tuebingen, Germany
| | - Martin Dreyling
- Agnieszka Korfel, Antonio Pezzutto, Eckhard Thiel, and Philipp Kiewe, Charité University Medicine Berlin; Thomas Grobosch, Labor Berlin - Charité Vivantes, Berlin; Uwe Schlegel, Ruhr-Universität Bochum, Bochum; Ulrich Herrlinger and Sied Kebir, University Hospital Bonn, Bonn; Martin Dreyling, Christian Schmidt, and Luisa von Baumgarten, Hospital of the Ludwig Maximilian University München, Munich; and Peter Martus, University Tuebingen, Tuebingen, Germany
| | - Christian Schmidt
- Agnieszka Korfel, Antonio Pezzutto, Eckhard Thiel, and Philipp Kiewe, Charité University Medicine Berlin; Thomas Grobosch, Labor Berlin - Charité Vivantes, Berlin; Uwe Schlegel, Ruhr-Universität Bochum, Bochum; Ulrich Herrlinger and Sied Kebir, University Hospital Bonn, Bonn; Martin Dreyling, Christian Schmidt, and Luisa von Baumgarten, Hospital of the Ludwig Maximilian University München, Munich; and Peter Martus, University Tuebingen, Tuebingen, Germany
| | - Luisa von Baumgarten
- Agnieszka Korfel, Antonio Pezzutto, Eckhard Thiel, and Philipp Kiewe, Charité University Medicine Berlin; Thomas Grobosch, Labor Berlin - Charité Vivantes, Berlin; Uwe Schlegel, Ruhr-Universität Bochum, Bochum; Ulrich Herrlinger and Sied Kebir, University Hospital Bonn, Bonn; Martin Dreyling, Christian Schmidt, and Luisa von Baumgarten, Hospital of the Ludwig Maximilian University München, Munich; and Peter Martus, University Tuebingen, Tuebingen, Germany
| | - Antonio Pezzutto
- Agnieszka Korfel, Antonio Pezzutto, Eckhard Thiel, and Philipp Kiewe, Charité University Medicine Berlin; Thomas Grobosch, Labor Berlin - Charité Vivantes, Berlin; Uwe Schlegel, Ruhr-Universität Bochum, Bochum; Ulrich Herrlinger and Sied Kebir, University Hospital Bonn, Bonn; Martin Dreyling, Christian Schmidt, and Luisa von Baumgarten, Hospital of the Ludwig Maximilian University München, Munich; and Peter Martus, University Tuebingen, Tuebingen, Germany
| | - Thomas Grobosch
- Agnieszka Korfel, Antonio Pezzutto, Eckhard Thiel, and Philipp Kiewe, Charité University Medicine Berlin; Thomas Grobosch, Labor Berlin - Charité Vivantes, Berlin; Uwe Schlegel, Ruhr-Universität Bochum, Bochum; Ulrich Herrlinger and Sied Kebir, University Hospital Bonn, Bonn; Martin Dreyling, Christian Schmidt, and Luisa von Baumgarten, Hospital of the Ludwig Maximilian University München, Munich; and Peter Martus, University Tuebingen, Tuebingen, Germany
| | - Sied Kebir
- Agnieszka Korfel, Antonio Pezzutto, Eckhard Thiel, and Philipp Kiewe, Charité University Medicine Berlin; Thomas Grobosch, Labor Berlin - Charité Vivantes, Berlin; Uwe Schlegel, Ruhr-Universität Bochum, Bochum; Ulrich Herrlinger and Sied Kebir, University Hospital Bonn, Bonn; Martin Dreyling, Christian Schmidt, and Luisa von Baumgarten, Hospital of the Ludwig Maximilian University München, Munich; and Peter Martus, University Tuebingen, Tuebingen, Germany
| | - Eckhard Thiel
- Agnieszka Korfel, Antonio Pezzutto, Eckhard Thiel, and Philipp Kiewe, Charité University Medicine Berlin; Thomas Grobosch, Labor Berlin - Charité Vivantes, Berlin; Uwe Schlegel, Ruhr-Universität Bochum, Bochum; Ulrich Herrlinger and Sied Kebir, University Hospital Bonn, Bonn; Martin Dreyling, Christian Schmidt, and Luisa von Baumgarten, Hospital of the Ludwig Maximilian University München, Munich; and Peter Martus, University Tuebingen, Tuebingen, Germany
| | - Peter Martus
- Agnieszka Korfel, Antonio Pezzutto, Eckhard Thiel, and Philipp Kiewe, Charité University Medicine Berlin; Thomas Grobosch, Labor Berlin - Charité Vivantes, Berlin; Uwe Schlegel, Ruhr-Universität Bochum, Bochum; Ulrich Herrlinger and Sied Kebir, University Hospital Bonn, Bonn; Martin Dreyling, Christian Schmidt, and Luisa von Baumgarten, Hospital of the Ludwig Maximilian University München, Munich; and Peter Martus, University Tuebingen, Tuebingen, Germany
| | - Philipp Kiewe
- Agnieszka Korfel, Antonio Pezzutto, Eckhard Thiel, and Philipp Kiewe, Charité University Medicine Berlin; Thomas Grobosch, Labor Berlin - Charité Vivantes, Berlin; Uwe Schlegel, Ruhr-Universität Bochum, Bochum; Ulrich Herrlinger and Sied Kebir, University Hospital Bonn, Bonn; Martin Dreyling, Christian Schmidt, and Luisa von Baumgarten, Hospital of the Ludwig Maximilian University München, Munich; and Peter Martus, University Tuebingen, Tuebingen, Germany
| |
Collapse
|
397
|
Langner-Lemercier S, Houillier C, Soussain C, Ghesquières H, Chinot O, Taillandier L, Soubeyran P, Lamy T, Morschhauser F, Benouaich-Amiel A, Ahle G, Moles-Moreau MP, Moluçon-Chabrot C, Bourquard P, Damaj G, Jardin F, Larrieu D, Gyan E, Gressin R, Jaccard A, Choquet S, Brion A, Casasnovas O, Colin P, Reman O, Tempescul A, Marolleau JP, Fabbro M, Naudet F, Hoang-Xuan K, Houot R. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro Oncol 2016; 18:1297-303. [PMID: 26951382 DOI: 10.1093/neuonc/now033] [Citation(s) in RCA: 127] [Impact Index Per Article: 15.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2015] [Accepted: 02/05/2016] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Treatment of relapsed/refractory (R/R) primary CNS lymphoma (PCNSL) is poorly defined, because randomized trials and large studies are lacking. The aim of this study was to analyze the characteristics, management, and outcome of R/R PCNSL patients after first-line therapy in a nationwide cohort. METHODS We analyzed R/R PCNSL patients following first-line treatment who had been prospectively registered in the database of the French network for oculocerebral lymphoma (LOC) between 2011 and 2014. RESULTS Among 563 PCNSL patients treated with first-line therapy, we identified 256 with relapsed (n = 93, 16.5%) or refractory (n = 163, 29.0%) disease. Patients who were asymptomatic at relapse/progression (25.5%), mostly diagnosed on routine follow-up neuroimaging, tended to have a better outcome. Patients who received salvage therapy followed by consolidation (mostly intensive chemotherapy plus autologous hematopoietic stem cell transplantation [ICT + AHSCT]) experienced prolonged survival compared with those who did not receive salvage or consolidation therapy. Independent prognostic factors at first relapse/progression were: KPS ≥ 70 vs KPS < 70), sensitivity to first-line therapy (relapsed vs refractory disease), duration of first remission (progression-free survival [PFS] ≥1 y vs <1 y), and management at relapse/progression (palliative care vs salvage therapy). Patients who relapsed early after first-line therapy (ie, PFS < 1 y) had a poor outcome, comparable to that of refractory patients. Conversely, patients experiencing late relapses (PFS ≥ 1 y) and/or undergoing consolidation with ICT + AHSCT experienced prolonged survival. CONCLUSIONS About a third of PCNSL patients are primary refractory to first line treatment. We identified several independent prognostic factors that can guide the management of R/R PCNSL patients.
Collapse
Affiliation(s)
- Sophie Langner-Lemercier
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Caroline Houillier
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Carole Soussain
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Hervé Ghesquières
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Olivier Chinot
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Luc Taillandier
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Pierre Soubeyran
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Thierry Lamy
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Franck Morschhauser
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Alexandra Benouaich-Amiel
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Guido Ahle
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Marie-Pierre Moles-Moreau
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Cécile Moluçon-Chabrot
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Pascal Bourquard
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Ghandi Damaj
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Fabrice Jardin
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Delphine Larrieu
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Emmanuel Gyan
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Remy Gressin
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Arnaud Jaccard
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Sylvain Choquet
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Annie Brion
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Olivier Casasnovas
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Philippe Colin
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Oumedaly Reman
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Adrian Tempescul
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Jean-Pierre Marolleau
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Michel Fabbro
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Florian Naudet
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Khê Hoang-Xuan
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| | - Roch Houot
- Department of Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France (S.L.-L.); Department of Neurology Mazarin, APHP, Sorbonne Universités UPMC Univ Paris VI, IHU, ICM, INCa-LOC Network, Groupe Hospitalier Pitié-Salpétrière, Paris, France (C.H., K.H.-X.); Department of Hematology, Hôpital René Huguenin-Institut Curie, Saint-Cloud, Collège de France, Paris, France (C.S.); Department of Hematology, Centre Léon Bérard, Lyon, France (H.G.); Department of Neurooncology, Centre Hospitalier Universitaire La Timone, Assistance Publique-Hôpitaux de Marseille, INSERM U911, CRO2, Université de la Méditerranée, Marseille, France (O.C.); Department of Neurology, Centre Hospitalier Universitaire de Nancy, Nancy, France (L.T.); Department of Hematology, Institut Bergonié, Bordeaux, France (P.S.); Department of Hematology, Centre Hospitalier Universitaire de Rennes, INSERM U917, Rennes, France (T.L., R.H.); Department of Hematology, Centre Hospitalier Universitaire de Lille, Lille, France (F.M.); Department of Neurology, Centre Hospitalier Universitaire Toulouse-Purpan, Toulouse, France (A.B.-A.); Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France (G.A.); Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France (M.-P.M.-M.); Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C.M.-C.); Department of Hematology and Oncology, Centre Hospitalier Universitaire de Nîmes, Nîmes, France (P.B.); Department of Hematology, Centre Hospitalier Universitaire de Caen, Caen, France (G.D., O.R.); Department of Hematology, Centre Henri Becquerel, Université de Rouen, INSERM U918, Rouen, France (F.J.); Department of Neurology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (D.L.); Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Tours, CIC, INSERM U1415, Tours, France (E.G.); Department of Hematology, Centre Hospitalier Unive
| |
Collapse
|
398
|
Wang Y, Tao RJ, He QW, Sun Y, Zhou SZ, Meng XJ, Zhu YF, Xu J. [High-dose pemetrexed in combination with temolozomide for the treatment of newly diagnosed primary central nervous system lymphoma]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2016; 37:242-4. [PMID: 27033765 PMCID: PMC7342948 DOI: 10.3760/cma.j.issn.0253-2727.2016.03.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Download PDF] [Subscribe] [Scholar Register] [Received: 09/23/2015] [Indexed: 11/25/2022]
Affiliation(s)
| | | | | | | | | | | | | | - J Xu
- Department of Neurosurgery, Shandong Cancer Hospital & Institute, Ji'nan 250117, China
| |
Collapse
|
399
|
Mylam KJ, Michaelsen TY, Hutchings M, Jacobsen Pulczynski E, Pedersen LM, Braendstrup P, Gade IL, Eberlein TR, Gang AO, Bøgsted M, Brown PDN, El-Galaly TC. Little value of surveillance magnetic resonance imaging for primary CNS lymphomas in first remission: results from a Danish Multicentre Study. Br J Haematol 2016; 176:671-673. [PMID: 26913572 DOI: 10.1111/bjh.13988] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Karen Juul Mylam
- Department of Haematology, Odense University Hospital, Odense, Denmark
| | | | - Martin Hutchings
- Department of Haematology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark
| | | | | | - Peter Braendstrup
- Department of Haematology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark
| | - Inger Lise Gade
- Department of Haematology, Aalborg University Hospital, Aalborg, Denmark
| | | | | | - Martin Bøgsted
- Department of Haematology, Aalborg University Hospital, Aalborg, Denmark.,Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark
| | - Peter de Nully Brown
- Department of Haematology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark
| | - Tarec Christoffer El-Galaly
- Department of Haematology, Aalborg University Hospital, Aalborg, Denmark.,Department of Clinical Medicine, Aalborg University Hospital, Aalborg, Denmark
| |
Collapse
|
400
|
Fraser E, Gruenberg K, Rubenstein JL. New approaches in primary central nervous system lymphoma. Chin Clin Oncol 2016; 4:11. [PMID: 25841718 DOI: 10.3978/j.issn.2304-3865.2015.02.01] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2014] [Accepted: 11/30/2014] [Indexed: 12/19/2022]
Abstract
Primary central nervous system lymphoma (PCNSL) has long been associated with an inferior prognosis compared to other aggressive non-Hodgkin's lymphomas (NHLs). However, during the past 10 years an accumulation of clinical experience has demonstrated that long-term progression-free survival (PFS) can be attained in a major proportion of PCNSL patients who receive dose-intensive consolidation chemotherapy and avoid whole brain radiotherapy. One recent approach that has reproducibly demonstrated efficacy for newly diagnosed PCNSL patients is an immunochemotherapy combination regimen used during induction that consists of methotrexate, temozolomide, and rituximab followed by consolidative infusional etoposide plus high-dose cytarabine (EA), administered in first complete remission (CR). Other high-dose chemotherapy-based consolidative regimens have shown efficacy as well. Our goal in this review is to update principles of diagnosis and management as well as data regarding the molecular pathogenesis of PCNSL, information that may constitute a basis for development of more effective therapies required to make additional advances in this phenotype of aggressive NHL.
Collapse
Affiliation(s)
- Eleanor Fraser
- Division of Hematology/Oncology, University of California, San Francisco, CA 94143, USA
| | - Katherine Gruenberg
- UCSF School of Pharmacy, University of California, San Francisco, CA 94143, USA
| | - James L Rubenstein
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.
| |
Collapse
|